WO2023220541A1 - Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors - Google Patents

Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors Download PDF

Info

Publication number
WO2023220541A1
WO2023220541A1 PCT/US2023/066601 US2023066601W WO2023220541A1 WO 2023220541 A1 WO2023220541 A1 WO 2023220541A1 US 2023066601 W US2023066601 W US 2023066601W WO 2023220541 A1 WO2023220541 A1 WO 2023220541A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
group
pyrido
methyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/066601
Other languages
English (en)
French (fr)
Inventor
Momar TOURE
Bin Li
Constantin Neagu
Yanping Wang
Theresa Johnson
Andrea UNZUE-LOPEZ
Yufang Xiao
Emily FRIIS
Maria DIPOTO
Satenig GULER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to CN202380052662.0A priority Critical patent/CN119546610A/zh
Priority to AU2023267747A priority patent/AU2023267747A1/en
Priority to EP23728556.4A priority patent/EP4522618A1/en
Priority to CA3250387A priority patent/CA3250387A1/en
Priority to IL316818A priority patent/IL316818A/en
Priority to JP2024566233A priority patent/JP2025521083A/ja
Publication of WO2023220541A1 publication Critical patent/WO2023220541A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • Hematopoietic progenitor kinase 1 is a serine/threonine kinase expressed in T cells, B-cells, and dendritic cells (Jr-Wen Shui, Nature Immunology, vol. 8, 2007, pp. 84-91).
  • HPK1 acts as a rheostat of T cell activation by regulating the molecular circuits of the T cell receptor (TCR) signaling pathway.
  • HPK1 is recruited to the TCR complex and phosphorylates SLP76 protein leading to its degradation and down-modulation of TCR signal strength. Genetic ablation of HPK1 results in T cell activation, lower TCR threshold, increased proliferation, and elevated levels of pro-inflammatory cytokines such as IL-2, TNF-a, and IFN-y. Loss of HPK1 expression enhances dendritic cell activation and antigen presentation.
  • HPK1 kinase activity is believed to be critical in conferring suppressive functions of HPK1 in a wide range of immune cells, such as CD8+, CD4+, DC, and NK to regulatory T cells (Tregs).
  • HPK1 knockout (KO) and kinase dead (KD) mice show enhanced T cell function and antitumor efficacy (You D. et. al., J. Immunother. Cancer, 2021). Therefore, pharmacological inhibition ofHPKl has the potential to enhance effector T cell function and antitumor activity.
  • a compound of Formula I wherein: R 1 and R 2 are each independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl; R1 and R2 together with the carbon to which they are attached can be taken together to form a C 3 -C 6 carbocyclic ring; R 3 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl; R 4 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl; R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl; R 7 is selected from the group consisting of
  • a compound of Formula I wherein R 1 and R 2 are hydrogen is provided.
  • R 3 is selected from the group consisting of hydrogen and -CH 3 is provided.
  • R4 is selected from the group consisting of hydrogen, ,Cl, -CH 2 CH 3 and -CH 3 is provided.
  • R5 and R6 are hydrogen is provided.
  • R7 is selected from the group consisting of hydrogen and -CH 3 is provided.
  • a compound of Formula I wherein X and Y are CH is provided.
  • a compound of Formula I wherein X and Y are N is provided. [0011] In an embodiment a compound of Formula I wherein X is N and Y is CH is provided. [0012] In an embodiment a compound of Formula I wherein W is CR8 is provided. [0013] In an embodiment a compound of Formula I wherein R 8 is selected from the group consisting of [0014] In an embodiment a compound of Formula I wherein R8 is selected from the group consisting of [0015] In an embodiment a compound of Formula I wherein R 8 is selected from the group consisting of [0016] In an embodiment a compound of Formula I wherein R8 is selected from the group consisting of
  • a compound of Formula I wherein R 8 is selected from the group consisting of [0018]
  • a compound of Formula I wherein R9 is selected from the group consisting of hydrogen, F. Cl, Br, I, -CF 3 , -CH 3 , -CH 2 CH 3 , [0019]
  • B is selected from the group consisting of R17 and R18 are each independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl; R 17 and R 18 together with the carbon to which they are attached can be taken together to form a C 3 -C 6 carbocyclic ring;
  • R19 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
  • R 20 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and
  • a compound of the Formula II wherein R 17 and R 18 are hydrogen is provided.
  • R19 is selected from the group consisting of hydrogen and -CH 3 is provided.
  • R20 is selected from the group consisting of hydrogen, ,Cl, -CH 2 CH 3 and -CH 3 is provided.
  • R 22 and R 23 are hydrogen is provided.
  • a compound of the Formula II wherein R21 is selected from the group consisting of hydrogen and -CH 3 is provided.
  • a compound of the Formula II wherein X’ and Y’ are CH is provided.
  • a compound of the Formula II wherein X’ and Y’ are N is provided.
  • a compound of the Formula II wherein X’ is N and Y’ is CH is provided.
  • a compound of the Formula II wherein r and s are 1 is provided.
  • a compound of the Formula II wherein R25, R26, R27 and are R 28 are hydrogen is provided.
  • a compound of the Formula II wherein R 25 and R 26 are -CH 3 and R27 and are R28 are hydrogen is provided.
  • a compound of the Formula II wherein R24 is selected from hydrogen, -CH 3 , -CF 3 , CH 2 F 2 and is provided.
  • R 29 and R 30 are each independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl; R29 and R30 together with the carbon to which they are attached can be taken together to form a C 3 -C 6 carbocyclic ring;
  • R31 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
  • R32 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl;
  • R 33 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
  • R 34 and R 35 are each independently selected from the group consisting
  • a compound of the Formula III wherein R29 and R30 are hydrogen is provided.
  • R 31 is selected from the group consisting of hydrogen and -CH 3 is provided.
  • R32 is selected from the group consisting of hydrogen, , Cl, -CH 2 CH 3 and -CH 3 is provided.
  • R 34 and R 35 are hydrogen is provided.
  • a compound of the Formula III wherein R33 is selected from the group consisting of hydrogen and -CH 3 is provided.
  • a compound of the Formula III wherein X’’ and Y’’ are CH is provided. [0039] In an embodiment a compound of the Formula III wherein X’’ and Y’’ are N is provided. [0040] In an embodiment a compound of the Formula III wherein X’’ is N and Y’’ is CH is provided. [0041] In an embodiment a compound of the Formula III wherein R 36 is selected from hydrogen, -CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 F 2 , and is provided. [0042] In an embodiment a compound of the Formula IV wherein: G is selected from the group consisting of
  • R37, R38, R39 and R40 are independently selected for each occurrence from the group consisting of hydrogen, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl; [0044] R 41 is independently selected for each position capable of substitution from the group consisting of hydrogen, halogen, -O-C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C1- C 6 alkyl and C 3 -C 6 cycloalkyl; or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof is provided. [0045] In an embodiment a compound of the Formula IV wherein R37 is -CH 3 is provided.
  • a compound of the Formula IV wherein R 38 is -CH 3 is provided.
  • a compound of the Formula IV wherein R39 and R40 is hydrogen is provided.
  • R 41 is selected from the group consisting of hydrogen, -OCH 3 and F is provided.
  • a compound of the Formula V wherein: J is selected from the group consisting of h is 1, 2 or 3 R42 is selected from the group consisting of C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl; or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof is provided.
  • a compound of the Formula V wherein h is 1 is provided.
  • a compound of the Formula V wherein R42 is -CH 3 is provided.
  • a compound of the Formula I selected from the group consisting of and pharmaceutically acceptable salts thereof is provided.
  • a compound of the Formula II selected from the group consisting of [0054]
  • a compound of the Formula IV selected from the group consisting of and pharmaceutically acceptable salts thereof is provided.
  • a compound of the Formula V selected from the group consisting of and pharmaceutically acceptable salts thereof is provided.
  • a pharmaceutical composition comprises a compound of Formula I, II, III, IV or V as defined above and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
  • a method is provided in which a therapeutically effective amount of the compound having the structure of Formula I, II, III, IV or V or a pharmaceutically acceptable salt thereof as defined above is administered to a patient having an HPK1-mediated disorder.
  • a method in which a therapeutically effective amount of the pharmaceutical composition that contains a compound of Formula I, II, III, IV or V and a pharmaceutically acceptable adjuvant, carrier, or vehicle, is administered to a patient having an HPK1-mediated disorder.
  • the HPK1- mediated disorder may be cancer or an autoimmune and/or inflammatory disease.
  • the HPK1-mediated disorder may be a cancer.
  • the cancer may be one or more of cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina, and vulva.
  • the HPK1-mediated disorder may be an autoimmune disease.
  • the autoimmune disease may be one or more of rheumatoid arthritis (RA), autoimmune pancreatitis (AIP), systemic lupus erythematosus (SLE), type I diabetes mellitus, multiple sclerosis (MS), antiphospholipid syndrome (APS), sclerosing cholangitis, systemic onset arthritis, irritable bowel disease (IBD), scleroderma, Sjogren's disease, vitiligo, polymyositis, pemphigus vulgaris, pemphigus foliaceus, inflammatory bowel disease including Crohn's disease and ulcerative colitis, autoimmune hepatitis, hypopituitarism, graft-versus-host disease (GvHD), autoimmune skin diseases, uveitis, pernicious anemia, and hypoparathyroidism.
  • RA rheumatoid arthritis
  • AIP autoimmune pancreatitis
  • SLE systemic lupus erythematos
  • Autoimmune diseases may also include, without limitation, polyangiitis overlap syndrome, Kawasaki's disease, sarcoidosis, glomerulonephritis, and cryopathy.
  • a compound of Formula I, II, III, IV or V or pharmaceutical composition thereof may be used to treat an inflammatory disorder and/or the immune response is associated with an inflammatory disorder.
  • the inflammatory disorder may be one or more of non-rheumatoid arthritis, kidney fibrosis, and liver fibrosis.
  • the inflammatory disorder may be an interface dermatitis.
  • the inflammatory disorder may be a skin disorder such as atopic dermatitis (eczema); a sterile inflammatory condition such as drug-induced liver and/or pancreas inflammation; an inflammatory liver disorder; and/or an inflammatory pancreatic disorder.
  • a skin disorder such as atopic dermatitis (eczema); a sterile inflammatory condition such as drug-induced liver and/or pancreas inflammation; an inflammatory liver disorder; and/or an inflammatory pancreatic disorder.
  • a therapeutically effective amount of the compound or pharmaceutical composition may be in a range consisting of 0.1 to 100 mg/kg of body weight of the patient, 0.1 to 50 mg/kg of body weight of the patient, 0.5 to 50 mg/kg of body weight of the patient, 1 to 20 mg/kg of body weight of the patient, 5 to 20 mg/kg of body weight of the patient, 10 to 20 mg/kg of body weight of the patient, 10 to 50 mg/kg of body weight of the patient, and 10 to 100 mg/kg of body weight of the patient.
  • the compound or pharmaceutical composition may be administered to the patient continuously, multiple times daily, once daily, once every other day, weekly, bi- weekly, monthly, or bi-monthly.
  • the compound or pharmaceutical composition may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir.
  • the compound may be administered subcutaneously, intravenously, intramuscularly, intra-articularly, intra- synovially, intrasternally, intrathecally, intrahepaticly, intralesionally, and by intracranial injection or infusion technique.
  • a kit is provided that includes a therapeutically effective amount of a compound of Formula I, II, III, IV or V as defined above or a physiologically acceptable salt or prodrug thereof; and instructions for use of the compound.
  • R1 and R2 are each independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl; R1 and R2 together with the carbon to which they are attached can be taken together to form a C 3 -C 6 carbocyclic ring;
  • R 3 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
  • R 4 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl;
  • R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and C 1 -C 6 haloalkyl;
  • R 7 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
  • R42 is selected from the group consisting of C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl;or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof.
  • An alkyl can be a straight or branched alkyl group. Exemplary alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl. The number of carbon atoms in the alkyl is not particularly limited. In some embodiments, an alkyl may have a specified number of carbon atoms such as 1- 6.
  • a halogen may refer to F, Cl, Br, or I.
  • a haloalkyl may refer to one or more halogens bonded to an alkyl.
  • An example of a haloalkyl may include CF 3 .
  • a heterocyclyl is a univalent group formed by removing a hydrogen atom from any ring atom of a heterocyclic compound. It may include one or more heteroatoms.
  • a heteroatom may refer to one or more of oxygen, sulfur, nitrogen, phosphorous, or any oxidized form thereof.
  • a heterocycle, heterocyclyl, and heterocyclic ring may be used interchangeably and refer to a stable 5 to 7-membered monocyclic or 6 to 14-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
  • saturated or partially unsaturated heterocyclic rings include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, oxazepinyl, thiazepinyl, and morpholinyl.
  • a heterocyclyl may include groups in a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, where the radical or point of attachment is on the heterocyclyl ring.
  • a heterocyclyl group may be a mono- or bicyclic.
  • Partially unsaturated may refer to a ring moiety that includes at least one double or triple bond. It may encompass rings that have multiple sites of unsaturation, but it not intended to include aryl or heteroaryl moieties. The term unsaturated may refer to a moiety that has one or more units of unsaturation.
  • An aryl may refer to an aryl alone or a larger moiety such as an aralkyl, aralkoxy, and/or aryloxyalkyl. It may refer to monocyclic and bicyclic rings. At least one ring in the system may be aromatic. Each ring in the system may contain 3-7 members. Exemplary aryl groups include, without limitation, phenyl, biphenyl, naphthyl, anthracyl, and the like, which optionally includes one or more substituents.
  • An aryl may also refer to a group in which an aromatic ring is fused to one or more non-aromatic rings such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, tetrahydronaphthyl, and the like.
  • a heteroaryl may refer to a heteroaryl alone or as a part of a larger moiety such as heteroaralkyl or heteroaralkoxy. It may refer to a group having 5-14 ring atoms, preferably 5 or 6 ring atoms. In addition to carbon atoms, the heteroaryl may include 1 to 5 heteroatoms as provided above.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
  • Heteroaryl may also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, and/or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-
  • a heteroaryl group is optionally mono- or bicyclic.
  • a heteroaralkyl may refer to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
  • the term optionally substituted may refer to one or more hydrogens of the designated moiety being replaced with a suitable substituent. Unless otherwise indicated, optionally substituted group has a suitable substituent at each substitutable position of the group and when more than one position in any given structure is substituted with more than one substituent selected from the specified group, the substituent is either the same or different at every position.
  • Typical substituents include, but are not limited to: -F, -Cl, -Br, -I, deuterium, -OH, protected hydroxy, alkoxy, oxo, thiooxo, -NO2, -CN, CF 3 , N3, -NH2, protected amino, -NH alkyl, -NH alkenyl, -NH alkynyl, -NH cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH -heterocyclic, -dialkylamino, - diarylamino, -diheteroarylamino, -O- alkyl, -O- alkenyl, -O- alkynyl, -O- cycloalkyl, - O-aryl, -O-heteroaryl, -O-heterocyclic, -C(O)- alkyl, -C(O)
  • the term stable may refer to compounds that are not substantially altered when subjected to conditions to allow for their production or synthesis, detection, recovery, purification, and/or use as disclosed herein.
  • a pharmaceutically acceptable salt may refer to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds disclosed herein include those derived from suitable inorganic and organic acids and bases.
  • suitable inorganic and organic acids and bases include those derived from suitable inorganic and organic acids and bases.
  • pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2 -naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pect
  • Salts may be derived from appropriate bases include alkali metal, alkaline earth metal, and ammonium salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate, and aryl sulfonate.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure.
  • isomeric e.g., enantiomeric, diastereomeric, and geometric (or conformational)
  • the enantiomeric excess is at least 50%, at least 60%, at least 70%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100%.
  • stereoisomers e.g., enantiomers, cis/trans isomers, conformers, and the like.
  • isomers can be separated by methods well known in the art, e.g., by liquid chromatography.
  • enantiomers e.g., by using chiral stationary phases.
  • an enantiomer may be isolated by converting it into a diastereomer, i.e., coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomer and cleavage of the auxiliary residue.
  • any enantiomer of a compound disclosed herein may be obtained from stereoselective synthesis using optically pure starting materials.
  • compounds disclosed herein may include isotope-labeled forms thereof.
  • An isotope-labeled form of a compound disclosed herein is identical to this compound apart from the fact that one or more atoms of the compound have been replaced by an atom or atoms having an atomic mass or mass number which differs from the atomic mass or mass number of the atom which usually occurs naturally.
  • isotopes which are readily commercially available and can be incorporated into a compound of the Formula I, II, III, IV or V by well-known methods include, without limitation, isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, for example 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively. It is also contemplated that a compound of the Formula I, II, III, IV or V, a prodrug thereof, or a pharmaceutically acceptable salt of either which contains one or more of the above-mentioned isotopes and/or other isotopes of other atoms are embodiments of the present disclosure.
  • An isotope-labeled compound of the Formula I, II, III, IV or V can be used in a number of beneficial ways.
  • an isotope-labeled compound of the Formula I, II, III, IV or V into which, for example, a radioisotope, such as 3 H or 14 C, has been incorporated is suitable for medicament and/or substrate tissue distribution assays.
  • radioisotopes are particularly preferred due to their ease of preparation and excellent detectability.
  • Incorporation of heavier isotopes, for example, deuterium ( 2 H) into a compound of the Formula I, II, III, IV or V may have therapeutic advantages due to the higher metabolic stability of this isotope-labeled compound.
  • An isotope-labeled compound of the Formula I, II, III, IV or V can be adapted to the procedures disclosed in the synthesis schemes and the related description, in the example part and in the preparation part, disclosed herein, replacing a non-isotope-labeled reactant by a readily available isotope-labeled reactant.
  • the compounds disclosed herein can be in the form of a prodrug compound.
  • a prodrug compound may refer to a derivative that is converted into a biologically active compound under physiological conditions in the living body, e.g., by oxidation, reduction, hydrolysis, or the like, each of which is carried out enzymatically, or without enzyme involvement.
  • prodrugs are compounds, wherein the amino group in a compound is acylated, alkylated, or phosphorylated; wherein the hydroxyl group is acylated, alkylated, phosphorylated, or converted into borate; wherein the carboxyl group is esterified or amidated; or wherein a sulfhydryl group forms a disulfide bridge with a carrier molecule, e.g., a peptide, that delivers the drug selectively to a target and/or to the cytosol of a cell.
  • a carrier molecule e.g., a peptide
  • prodrugs are compounds, wherein the carboxylate in a compound is for example converted into an alkyl-, aryl-, choline-, amino, acyloxymethylester, or linolenoyl-ester.
  • a composition comprising a compound disclosed herein or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the amount of compound in compositions disclosed herein may be effective to measurably inhibit HPK1, or a mutant thereof, in a biological sample or in a patient.
  • a therapeutically effective amount of the compound may be administered to a patient in need thereof.
  • a patient or subject may refer to an animal, preferably a mammal, and even more preferably, a human.
  • a biological sample may refer to, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle may refer to a nontoxic carrier, an adjuvant, or a vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • compositions disclosed herein include, without limitation, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial
  • compositions disclosed herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir.
  • Parenteral administration may refer to subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques.
  • the composition may be administered orally, intraperitoneally, orintravenously.
  • Sterile injectable forms of the compositions disclosed herein include aqueous oroleaginous suspension. These suspensions are formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectablepreparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils may be conventionally employed as a solvent or suspending medium.
  • Pharmaceutically acceptable compositions disclosed herein may be orally administered in any orally acceptable dosage form.
  • Exemplary oral dosage forms are capsules, tablets, aqueous suspensions, or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are required for oral use, the active ingredient may be combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring, and/or coloring agents may be optionally added.
  • pharmaceutically acceptable compositions disclosed herein are formulated for oral administration. Such formulations may be administered with or without food.
  • compositions may be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the compound can be administered to a patient receiving these compositions.
  • the dosage is between 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 0.5 to 50 mg/kg, 1 to 50 mg/kg, 1 to 20 mg/kg, 5 to 20 mg/kg, 10 to 20 mg/kg, 10-50 mg/kg of body weight of the patient, or 10-100 mg/kg of body weight of the patient or any other dosing range disclosed herein.
  • the compounds or compositions herein are administered continuously, multiple times daily, once daily, once every other day, weekly, bi-weekly, monthly, or bi-monthly.
  • a therapeutically effective amount of a compound or composition herein may vary according to factors known in the art, but a dose of about 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 0.5-50 mg/kg, 1 to 50 mg/kg, 1 to 20 mg/kg, 5 to 20 mg/kg, 10 to 20 mg/kg, or 10-50 mg/kg of body weight of the patient, or 10-100 mg/kg of body weight of the patient or any other dosing range disclosed herein, may be therapeutically effective.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of a compound disclosed herein in the composition will also depend upon the particular compound in the composition.
  • the compounds of Formula I, II, III, IV or V disclosed herein can be administered before or following an onset of disease once or several times acting as therapy.
  • the aforementioned compounds and medical products of the inventive use are particularly used for the therapeutic treatment.
  • a therapeutically relevant effect relieves to some extent one or more symptoms of a disorder, or returns to normality, either partially or completely, one or more physiological or biochemical parameters associated with or causative of a disease or pathological condition.
  • Monitoring is considered as a kind of treatment provided that the compounds are administered in distinct intervals, e.g., in order to boost the response and eradicate symptoms of the disease completely. Either the identical compound or different compounds can be applied.
  • the methods disclosed herein can also be used to reduce the likelihood of developing a disorder or even prevent the initiation of disorders associated with HPK1 activity in advance or to treat the arising and continuing symptoms.
  • the host or patient can belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats, and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for treatment of human disease.
  • the compounds disclosed herein may be useful as anticancer agents for cancers that are responsive to HPK1 inhibition.
  • the cancer may include, without limitation, cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina, and vulva.
  • the cancer is a mesothelioma, sarcoma, retinoblastoma, Wilms tumor, leukemia, lymphoma, non-Hodgkin disease, chronic and acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin disease, multiple myeloma, T-cell lymphoma, myelodysplastic syndrome, plasma cell neoplasia, and paraneoplastic syndromes.
  • the compounds of Formula I, II, III, IV or V may be used in a method for ameliorating symptoms associated with and/or treating unwanted immune activation, including, but not limited to, symptoms associated with and/or treatment of autoimmunity.
  • the disclosed compounds may be useful to inhibit the immune response and thereby prevent or delay development of the autoimmune disease.
  • the autoimmune disease may be characterized by joint pain, antinuclear antibody positivity, malar rash, or discoid rash.
  • the autoimmune disease may be associated with the skin, muscle tissue, and/or connective tissue. In some embodiments, the autoimmune disease is not evidenced in the individual by skin, muscle tissue, and/or connective tissue symptoms. In some embodiments, the autoimmune disease is systemic.
  • Autoimmune diseases include, without limitation, rheumatoid arthritis (RA), autoimmune pancreatitis (AIP), systemic lupus erythematosus (SLE), type I diabetes mellitus, multiple sclerosis (MS), antiphospholipid syndrome (APS), sclerosing cholangitis, systemic onset arthritis, irritable bowel disease (IBD), scleroderma, Sjogren's disease, vitiligo, polymyositis, pemphigus vulgaris, pemphigus foliaceus, inflammatory bowel disease including Crohn's disease and ulcerative colitis, autoimmune hepatitis, hypopituitarism, graft-versus-host disease (GvHD), autoimmune skin diseases, uveitis, pernicious anemia, and hypoparathyroidism.
  • RA rheumatoid arthritis
  • AIP autoimmune pancreatitis
  • SLE systemic lupus erythematos
  • Autoimmune diseases may also include, without limitation, polyangiitis overlap syndrome, Kawasaki's disease, sarcoidosis, glomerulonephritis, and cryopathy.
  • the disclosed compounds may be used to treat an inflammatory disorder and/or the immune response is associated with an inflammatory disorder.
  • the term “inflammatory disorder” may encompass autoimmune diseases, as well as inflammatory conditions without a known autoimmune component (e.g., atherosclerosis, asthma, etc.).
  • inhibiting the immune response may alleviate or mitigate one or more symptoms of the inflammatory disorder.
  • Inhibiting the immune response may be useful to treat the inflammatory disorder and/or prevent or delay development of the inflammatory disorder.
  • the inflammatory disorder may include, without limitation, non-rheumatoid arthritis, kidney fibrosis, and liver fibrosis.
  • the inflammatory disorder may be an interface dermatitis.
  • the interface dermatitis may be one or more of lichen planus, lichenoid eruption, lichen planus-like keratosis, lichen striatus, keratosis lichenoides chronica, erythema multiforme, fixed drug eruption, pityriasis lichenoides, phototoxic dermatitis, radiation dermatitis, viral exanthems, dermatomyositis, secondary syphilis, lichen sclerosus et atrophicus, mycosis fungoides, bullous pemphigoid, lichen aureus, porokeratosis, acrodermatitis chronicus atrophicans, and regressing melanoma.
  • the inflammatory disorder may be a skin disorder such as atopic dermatitis (eczema); a sterile inflammatory condition such as drug-induced liver and/or pancreas inflammation; an inflammatory liver disorder; and/or an inflammatory pancreatic disorder.
  • a skin disorder such as atopic dermatitis (eczema); a sterile inflammatory condition such as drug-induced liver and/or pancreas inflammation; an inflammatory liver disorder; and/or an inflammatory pancreatic disorder.
  • Sensitivity of a given cancer to HPK1 inhibition can be assessed by, without limitation, measurement of a decrease in primary or metastatic tumor load (minor, partial, or complete regression), alterations in the hemogram, altered hormone or cytokine concentrations in the blood, inhibition of further increase of tumor load, stabilization of the disease in the patient, assessment of biomarkers or surrogate markers relevant for the disease, prolonged overall survival of a patient, prolonged time to disease progression of a patient, prolonged progression-free survival of a patient, prolonged disease-free survival of a patient, improved quality of life of a patient, or modulation of the co-morbidity of the disease (for example, but not limited to, pain, cachexia, mobilization, hospitalization, altered hemogram, weight loss, wound healing, fever).
  • compounds of Formula I, II, III, IV or V and related formulae exhibit an IC50 for the inhibiting HPK1 of less than about 1000 nM, less than about 500 nM, less than 100 nM, less than 500 nM, or less than 1000 nM.
  • the compounds of formula (I), and related formulae exhibit an IC 50 for the inhibiting HPK1 of at least 1 nM, at least 10 nM, at least 100 nM, or at least 500 nM. In some embodiments, the range is a combination of these values.
  • Compounds of Formula I, II, III, IV or V and/or a pharmaceutically acceptable salt thereof can be employed as an intermediate for the preparation of further medicament active ingredients.
  • the medicament is preferably prepared in a non-chemical manner, e.g., by combining the active ingredient with at least one solid, fluid and/or semi-fluid carrier or excipient, and optionally in conjunction with a single or more other active substances in an appropriate dosage form.
  • a medicament is provided herein that can include at least one compound disclosed herein or a prodrug or pharmaceutically acceptable salt thereof including mixtures thereof in all ratios.
  • a medicament may refer to any agent in the field of medicine, which comprises one or more compounds of Formula I, II, III, IV or V or preparations thereof (e.g., a pharmaceutical composition or pharmaceutical formulation) and can be used in prophylaxis, therapy, follow-up or aftercare of patients who suffer from diseases, which are associated with HPK1 activity, in such a way that a pathogenic modification of their overall condition or of the condition of particular regions of the organism could establish at least temporarily.
  • the active ingredient may be administered alone or in combination with other treatments.
  • a synergistic effect may be achieved by using more than one compound in the pharmaceutical composition, i.e. the compound of Formula I, II, III, IV or V may be combined with at least another agent as active ingredient, which is either another compound of Formula I, II, III, IV or V or a compound of different structural scaffold.
  • the active ingredients can be used either simultaneously or sequentially.
  • the HPK1 inhibitor compounds disclosed herein is administered simultaneously with one or more additional therapeutic agents.
  • sequential administration includes administering the HPK1 inhibitor or additional therapeutic agent followed within about any of one minute, five minutes, 30 minutes, one hour, five hours, 24 hours, 48 hours, or a week.
  • the HPK1 inhibitor is administered by the same route of administration as the additional therapeutic agent.
  • the HPK1 inhibitor may be administered by a different route of administration than the additional therapeutic agent.
  • a therapeutic agent may include, without limitation, an anti- inflammatory drug and/or one or more anti-tumor agents conventionally used in chemotherapy or targeted therapy.
  • the compounds or compositions disclosed herein may be used as a monotherapy or may be combined with therapeutic agents.
  • anti-tumor agents include, without limitation, platinum compounds such as carboplatin, cisplatin, picoplatin, and the like; alkylating agents such as altretamine, carmustine, chlorambucil, mitobronitol, apaziquone, palifosfamide, and the like; DNA altering agents such as bisantrene, decitabine, mitoxantrone, procarbazine, and the like; microtubule modifiers such as docetaxel, eribulin, paclitaxel, vinblastine, and the like; topoisomerase inhibitor such as etoposide, razoxane, topotecan, and the like; anticancer antibodies such as bleomycin, mitomycin C, and the like; antimetabolites such as capecitabine, cladribine, and the like; hormones or antagonists such as tamoxifen, dexamethasone, and the like; cytokines such as interferon and the like; antibodies
  • a method for inhibiting abnormal cell growth in a mammal, preferably a human, or treating a cancer may include administering to the mammal an amount of a compound of Formula I, II, III, IV or V disclosed herein, or a prodrug or a pharmaceutically acceptable salt thereof, in combination with radiation therapy, wherein the amounts of the compound, salt, or prodrug, is in combination with the radiation therapy effective in inhibiting abnormal cell growth or treating the cancer or symptoms thereof in the mammal.
  • Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein.
  • treatment may refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment is administered after one or more symptoms have developed.
  • treatment is administered in the absence of symptoms.
  • treatment is administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment is also continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • kits that includes separate packs of a therapeutically effective amount of a compound disclosed herein or a physiologically acceptable salt, or prodrug thereof, and optionally, a therapeutically effective amount of a therapeutic agent.
  • the kit may include suitable containers, such as boxes, individual bottles, bags, or ampoules as well as instructions for using or applying the kit.
  • the kit may, for example, contain separate ampoules, each containing a therapeutically effective amount of a compound disclosed herein and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further therapeutic agent in dissolved or lyophilized form.
  • deuterated solvents contained typically 0.03% to 0.05% v/v tetramethylsilane, which was used as the reference signal (set at d 0.00 for both 1H and 13C). In cases where the deuterated solvents did not contain tetramethylsilane, the residual non-deuterated solvent peaks were used as a reference signal, as per published guidelines (J. Org. Chem., vol.62, No.21, 1997).
  • LC-MS analyses were performed one either one of the two following instruments: 1. SHIMADZU LC-MS machine consisting of an UFLC 20-AD system and LCMS 2020 MS detector. The column used was a Shim-pack XR-ODS, 2.2 ⁇ m, 3.0 x 50 mm.
  • a linear gradient was applied, starting at 95% A (A: 0.05% trifluoroacetic acid (TFA) in water) and ending at 100% B (B: 0.05% TFA in acetonitrile (ACN)) over 2.2 min. with a total run time of 3.6 min.
  • the column temperature was at 40 °C with the flow rate at 1.0 mL/min.
  • the Diode Array detector was scanned from 200- 400 nm.
  • the mass spectrometer was equipped with an electro spray ion source (ES) operated in a positive or negative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time of 0.6 s. 2.
  • Agilent 1200 Series mass spectrometers from Agilent Technologies, using either Atmospheric Chemical Ionization (APCI) or Electrospray Ionization (ESI).
  • APCI Atmospheric Chemical Ionization
  • ESI Electrospray Ionization
  • Diode Array detector was scanned from 200-400 nm.
  • the mass spectrometer was scanned between m/z 90-900 with a scan time of 0.6 s.
  • HPLC data were either obtained from the SHIMAZU LC-MS machine or using Agilent 1100 series HPLC from Agilent technologies using a column (XBridge C8, 3.5 ⁇ m, 4.6 x 50 mm) and two mobile phases (mobile phase A: water + 0.1 % TFA; mobile phase B: ACN + 0.1 % TFA).
  • the flow rate was 2 mL/min.
  • the gradient method was: 0 min.: 5 % B; 8 min.: 100 % B; 8.1 min.: 100 % B; 8.5 min.: 5% B; 10 min.5% B, unless otherwise indicated.
  • the compounds according to Formula I, II, III, IV or V and related formulae described herein can be prepared from readily available starting materials. If such starting materials are not commercially available, they may be prepared by standard synthetic techniques. In general, the synthesis pathways for any individual compound of Formula I, II, III, IV or V and related formulae will depend on the specific substituents of each molecule, such factors being appreciated by those of ordinary skilled in the art. The following general methods and procedures described hereinafter in the examples may be employed to prepare compounds of Formula I, II, III, IV or V and related formulae. Reaction conditions depicted in the following schemes, such as temperatures, solvents, or co-reagents, are given as examples only and are not restrictive.
  • Example 1 synthesis of compound 1 N1-[2-(dimethylamino) ethyl]-2-fluoro-N4- (7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)benzene-1,4-diamine [00105] N-[2-(dimethylamino)ethyl]-2-fluoro-4-nitroaniline: A solution of 1,2-difluoro-4-nitrobenzene (3.00 g; 17.91 mmol) and (2-aminoethyl)dimethylamine (1.70 g; 18.32 mmol) and TEA ⁇ triethylamine ⁇ (5.49 mL; 37.55 mmol) in AcOEt ⁇ ethyl acetate ⁇ (100.00 mL) was stirred for overnight at 80
  • tert-butyl N-[2-(dimethylamino)ethyl]-N-(2-fluoro-4- nitrophenyl)carbamate A solution of N-[2-(dimethylamino)ethyl]-2-fluoro-4- nitroaniline (3.67 g; 15.85 mmol) and (Boc)2O (17.25 mL; 76.61 mmol) and DMAP ⁇ 4-Dimethylaminopyridine ⁇ (200.00 mg; 1.47 mmol) and TEA (6.30 mL; 43.06 mmol) in DCM ⁇ dichloromethane ⁇ (50.00 mL) was stirred for overnight at room temperature under nitrogen atmosphere.
  • tert-butyl N-(4-amino-2-fluorophenyl)-N-[2- (dimethylamino)ethyl]carbamate A solution of tert-butyl N-[2- (dimethylamino)ethyl]-N-(2-fluoro-4-nitrophenyl)carbamate (4.90 g; 14.97 mmol) and NH 4 Cl (4.00 g; 74.03 mmol) and Fe (4.00 g; 70.19 mmol) in water (32.00 mL) and EtOH (48.00 mL) was stirred for 3 h at 80 degree C under nitrogen atmosphere. The resulting mixture was concentrated under vacuum.
  • tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d] pyrimidine-7- carboxylate To a solution of tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4- d]pyrimidine-7-carboxylate (20.00 g; 62.46 mmol) in EtOH (400.00 mL) was added Zn (22.00 g; 319.67 mmol) and NH4OH (24.00 mL) at room temperature. The resulting mixture was stirred for 15 h at 90 o C under N 2 atmosphere.
  • tert-butyl 7-bromo-8-methyl-2H,3H-pyrido[2,3-b] [1,4]oxazine-1- carboxylate To a stirred solution of 7-bromo-8-methyl-1H,2H,3H-pyrido[2,3-b][1,4] oxazine (59.00 g, 239.53 mmol), TEA (107.83 mL, 736.94 mmol) and DMAP (6.40 g, 49.77 mmol) in DCM (350 mL) was added Boc 2 O (169.30 g, 736.94 mmol) in DCM (150.00 mL) dropwise at 0 o C.
  • Example 2 synthesis of compound 22-(azetidin-1-yl)-N- ⁇ 4-[(6- ⁇ 8-chloro- 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3- yl)amino]-2-methylphenyl ⁇ acetamide [00117] tert-butyl 7-[(3-methyl-4-nitrophenyl)amino]-1,2,3,4-tetrahydro- 2,6-naphthyridine-2-carboxylate: To a stirred solution of tert-butyl 7-chloro- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (400.00 mg; 1.46 mmol) and 3- methyl-4-nitroaniline (271.84 mg; 1.75 mmol) in 1,4-
  • N-(3-methyl-4-nitrophenyl)-5,6,7,8-tetrahydro-2,6-naphthyridin-3- amine To a stirred solution of tert-butyl 7-[(3-methyl-4-nitrophenyl)amino]-1,2,3,4- tetrahydro-2,6-naphthyridine-2-carboxylate (330.00 mg; 0.86 mmol; 1.00 eq.) in DCM (15.00 mL) was added TFA (3.00 mL) in portion at room temperature. After stirring for 1 h at room temperature, the mixture was basified to pH [7] with saturated NaHCO3 (aq.).
  • tert-butyl 7-bromo-8-chloro-1H,2H,3H-pyrido[2,3-b] [1,4] oxazine- 1-carboxylate To a stirred solution of 7-bromo-8-chloro-1H,2H,3H-pyrido[2,3- b][1,4] oxazine (340.00 mg; 1.18 mmol) and Di-tert-butyl dicarbonate (897.00 mg; 3.90 mmol) in Dichloromethane (5.00 mL) were added Triethylamine (0.57 mL; 3.91 mmol) and N,N-dimethylpyridin-4-amine (34.00 mg; 0.26 mmol) in portions at room temperature under N2 atmosphere.
  • tert-butyl 7- ⁇ 7-[(4-amino-3-methylphenyl)amino]-1,2,3,4- tetrahydro-2,6-naphthyridin-2-yl ⁇ -8-chloro-1H,2H,3H-pyrido[2,3-b][1,4]oxazine- 1-carboxylate To a solution of tert-butyl 8-chloro-7- ⁇ 7-[(3-methyl-4- nitrophenyl)amino]-1,2,3,4-tetrahydro-2,6-naphthyridin-2-yl ⁇ -1H,2H,3H-pyrido[2,3- b][1,4]oxazine-1-carboxylate (110.00 mg; 0.19 mmol) in MeOH (10.00 mL) was added Raney-Ni (20.04 mg; 0.22 mmol) at room temperature.
  • Example 3 synthesis of compound 32-(azetidin-1-yl)-N- ⁇ 2-methyl-4-[(7- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)amino]phenyl ⁇ acetamide
  • tert-butyl 2-[(3-methyl-4-nitrophenyl)amino]-5H,6H,7H,8H- pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred mixture of tert-butyl 2-chloro- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (800.00 mg; 2.89 mmol) and 3- methyl-4-nitroaniline (590.00 mg; 3.76 mmol) in 1,4
  • tert-butyl 8-methyl-7- ⁇ 2-[(3-methyl-4-nitrophenyl)amino]- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl ⁇ -1H,2H,3H-pyrido[2,3-b][1,4]oxazine- 1-carboxylate To a stirred mixture of N-(3-methyl-4-nitrophenyl)-5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine (700.00 mg; 2.45 mmol) and tert-butyl 7-bromo-8- methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (600.00 mg; 1.64 mmol) in 1,4-dioxane (15.00 mL) were added Cs2CO3 (1.90 g; 5.54 m
  • tert-butyl N-(2-fluoro-4-nitrophenyl)-N-[2-(morpholin-4- yl)ethyl]carbamate To a stirred solution of 2-fluoro-N-[2-(morpholin-4-yl)ethyl]-4- nitroaniline (6.20 g; 22.23 mmol) and Di-tert-butyl dicarbonate (15.00 g; 65.29 mmol) in dichloromethane (100.00 mL) were added Triethylamine (9.62 mL; 65.72 mmol) and N,N-dimethylpyridin-4-amine (563.00 mg; 4.38 mmol) in portions at room temperature under N2 atmosphere.
  • tert-butyl N-(4-amino-2-fluorophenyl)-N-[2-(morpholin-4- yl)ethyl]carbamate To a stirred solution of tert-butyl N-(2-fluoro-4-nitrophenyl)-N- [2-(morpholin-4-yl)ethyl]carbamate (7.00 g; 18.95 mmol) in EtOH (3.00 mL) and water (2.00 mL) were added NH 4 Cl (4.00 g; 74.03 mmol) and Fe (5.30 g; 89.91 mmol) in portions at room temperature under N2 atmosphere. The solid was filtered out.
  • the resulting mixture was stirred for 16 h at 100 o C under N 2 atmosphere. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 5 synthesis of compound 55-chloro-6-(methanesulfonylmethyl)-N-(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)pyridin-3-amine
  • 5-bromo-2-(bromomethyl)-3-chloropyridine To a stirred mixture of (5-bromo-3-chloropyridin-2-yl) methanol (1.00 g; 3.96 mmol) in DCM (30 mL) was added PBr3 (0.51 mL; 5.15 mmol) in dropwise at -78 o C.
  • tert-butyl 7-(2- ⁇ [5-chloro-6-(methanesulfonylmethyl) pyridin-3-yl] amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl)-8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazine-1-carboxylate To a solution of 5-chloro-6- (methanesulfonylmethyl)-N- ⁇ 5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-2-yl ⁇ pyridin-3- amine (100.00 mg; 0.26 mmol) and tert-butyl 7-bromo-8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazine-1-carboxylate (86.00 mg; 0.26 mmol) in
  • the resulting mixture was stirred for 4 h at 25 o C under nitrogen atmosphere.
  • the resulting mixture was extracted with DCM.
  • the combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 6 synthesis of compound 62-fluoro-N4-(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)-N1-[2- (morpholin-4-yl)ethyl]benzene-1,4-diamine [00153] tert-butyl N-[2-fluoro-4-( ⁇ 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl ⁇ amino)phenyl]-N-[2-(morpholin-4-yl)ethyl]carbamate: To a stirred solution of tert-butyl N-(4-amino-2-fluorophenyl)-N-[2-(morpholin-4-yl)ethyl]carbamate (400.00 mg;
  • the resulting mixture was stirred for 2 h at 100 o C under N 2 atmosphere.
  • the resulting mixture was diluted with water (50 mL), extracted with EtOAc (3 x 50 mL).
  • the combined organic layers were washed with brine 50 mL) and dried over anhydrous Na 2 SO 4 .
  • the resulting mixture was concentrated under reduced pressure.
  • the resulting mixture was stirred for overnight at 100 o C under N 2 atmosphere.
  • the resulting mixture was diluted with water (50 mL), extracted with EtOAc (3 x 50 mL).
  • the combined organic layers were washed with brine (50 mL) and dried over anhydrous Na2SO4.
  • the resulting mixture was concentrated under reduced pressure.
  • Example 7 synthesis of compound 72-[(6- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl) amino]-6-(propan-2- yl)-4H,5H,6H,7H,8H-pyrazolo[1,5-d] [1,4] diazepin-7-one [00157] methyl 2-(3-bromo-5-methyl-1H-pyrazol-1-yl)acetate: To a stirred solution of 3-bromo-5-methyl-1H-pyrazole (20.00 g; 118.01 mmol), tetra-n- butylammonium iodide (TBAI) (2.40 g; 6.17 mmol) and K 2 CO 3 (31.10 g; 213.78 mmol) in DMF (200.00 mL) was added
  • methyl 2-[3-bromo-5-(bromomethyl)-1H-pyrazol-1-yl]acetate To a stirred solution of methyl 2-(3-bromo-5-methyl-1H-pyrazol-1-yl)acetate (25.00 g; 107.27 mmol) and NBS (20.10 g; 107.27 mmol) in PhCF 3 (500.00 mL) was added 2- [(1Z)-2-(1-cyano-1-methylethyl)diazen-1-yl]-2-methylpropanenitrile (18.54 g; 107.27 mmol) in portions at room temperature under N2 atmosphere.
  • methyl 2-[3-bromo-5-(cyanomethyl)-1H-pyrazol-1-yl]acetate To a stirred solution of methyl 2-[3-bromo-5-(bromomethyl)-1H-pyrazol-1-yl]acetate (22.00 g; 50.25 mmol) in DMSO (200.00 mL) were added sodium cyanide (3.77 g; 75.38 mmol) and water (4.00 mL; 219.76 mmol) in portions at room temperature under N 2 atmosphere. The resulting mixture was stirred for 1 h at 25 o C under N 2 atmosphere. The resulting mixture was quenched with FeSO4 (aq.), extracted with EtOAc (3 x 100 mL).
  • Example 8 synthesis of compound 83-methyl-N- ⁇ 5-[(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-2-yl) amino] pyridin-2-yl ⁇ oxetane-3-carboxamide [00169] To a stirred solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d] pyrimidine-7-carboxylate (1037.00 mg; 3.77 mmol) and N-(5-aminopyridin-2-yl) acetamide (500.00 mg; 3.14 mmol) in 1,4-dioxane (50.00 mL) were added PEPPSI TM - IPr (269.00 mg; 0.31 mmol) and Cs 2 CO 3 (2
  • the resulting mixture was stirred for 3 h at room temperature.
  • the resulting mixture was purified by Prep-HPLC with the following condition (Column: Xselect CSH C18 OBD Column 30*150 mm, 5 ⁇ m, n; Mobile Phase A: water (0.1%FA), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 3% B to 25% B in 8 min, 25% B; Wavelength: 254/220 nm; RT1 (min.): 7.4).
  • Example 9 Synthesis of compound 92-(azetidin-1-yl)-N- ⁇ 2-methyl-4-[(6- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6- naphthyridin-3-yl) amino] phenyl ⁇ acetamide [00176] tert-butyl 7-[(3-methyl-4-nitrophenyl) amino]-1,2,3,4-tetrahydro- 2,6-naphthyridine-2-carboxylate: To a stirred solution of tert-butyl 7-chloro- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (800.00 mg; 2.92 mmol) and 3- methyl-4-nitroaniline (543.69 mg; 3.50 mmol) in 1,4-dioxan
  • tert-butyl 7- ⁇ 7-[(4-amino-3-methylphenyl) amino]-1,2,3,4- tetrahydro-2,6-naphthyridin-2-yl ⁇ -8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4]oxazine-1-carboxylate To a stirred solution of tert-butyl 8-methyl-7- ⁇ 7-[(3- methyl-4-nitrophenyl)amino]-1,2,3,4-tetrahydro-2,6-naphthyridin-2-yl ⁇ -1H,2H,3H- pyrido[2,3-b][1,4]oxazine-1-carboxylate (130.00 mg; 0.19 mmol) and Fe (56.74 mg; 0.96 mmol) in EtOH (6.00 mL) and H 2 O (4.00 mL) was added NH 4 Cl (43.36
  • oxazine-1-carboxylate To a stirred solution of tert- butyl 7- ⁇ 7-[(4-amino-3-methylphenyl)amino]-1,2,3,4-tetrahydro-2,6-naphthyridin-2- yl ⁇ -8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (90.00 mg; 0.16 mmol) and 2-(azetidin-1-yl)acetic acid hydrochloride (49.
  • Example 10 synthesis of compound 10 N- ⁇ 2-methyl-4-[(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b] [1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl)amino]phenyl ⁇ -2-(pyrrolidin-1-yl)acetamide
  • tert-butyl 2-[(3-methyl-4-nitrophenyl) amino]-5H,6H,7H,8H- pyrido[3,4-d] pyrimidine-7-carboxylate To a stirred mixture of tert-butyl 2-chloro- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (800.00 mg; 2.89 mmol) and 3- methyl-4-nitroaniline (590.00 mg; 3.76 mmol) in 1,4-
  • N-(3-methyl-4-nitrophenyl)-5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-2-amine To a stirred mixture of tert-butyl 2-[(3-methyl-4-nitrophenyl) amino]-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (980.00 mg; 2.54 mmol) in DCM (20.00 mL) was added TFA (4.00 mL) in portions at 25 o C. The resulting mixture was stirred for 2 h at 25 o C under nitrogen atmosphere. The reaction was diluted with NaHCO3 (aq.) at 25 o C.
  • Example 11 synthesis of compound 11 N- ⁇ 4-[(3R)-3-(dimethylamino) pyrrolidine-1-carbonyl] phenyl ⁇ -6- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3-amine [00190] tert-butyl 7- ⁇ [4-(methoxycarbonyl) phenyl] amino ⁇ -1,2,3,4- tetrahydro-2,6-naphthyridine-2-carboxylate: To a stirred solution of methyl 4- aminobenzoate (235.00 mg; 1.55 mmol) and tert-butyl 7-chloro-1,2,3,4-tetrahydro- 2,6-naphthyridine-2-carboxylate (400.00 mg; 1.41 mmol) in 1,4-d
  • tert-butyl 7-(7- ⁇ [4-(methoxycarbonyl)phenyl]amino ⁇ -1,2,3,4- tetrahydro-2,6-naphthyridin-2-yl)-8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazine-1-carboxylate To a solution of methyl 4-[(5,6,7,8-tetrahydro-2,6- naphthyridin-3-yl)amino]benzoate (60.00 mg; 0.21 mmol) and tert-butyl 7-bromo-8- methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (82.00 mg; 0.23 mmol) in 1,4-dioxane (15.00 mL) were added Cs 2 CO 3 (145.00 mg; 0.42 mmol) and P
  • the resulting mixture was stirred for 2 h at 25 o C.
  • the mixture was basified to pH [7] with saturated NaHCO 3 (aq.).
  • the resulting mixture was extracted with EtOAc.
  • the combined organic layers were washed with NaCl (aq.) and dried over anhydrous Na 2 SO 4 .
  • Example 12 synthesis of compound 12 N- ⁇ 4-[(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl ⁇ -2- (morpholin-4-yl)acetamide [00197] tert-butyl 2-[(4-nitrophenyl) amino]-5H,6H,7H,8H-pyrido[3,4-d] pyrimidine-7-carboxylate: To a solution of tert-butyl 2-chloro-5H,6H,7H,8H- pyrido[3,4-d] pyrimidine-7-carboxylate (600.00 mg; 2.22 mmol) and 4-nitroaniline (383.00 mg; 2.67 mmol) in 1,4-dioxane (15.00 mL) were
  • tert-butyl 8-methyl-7- ⁇ 2-[(4-nitrophenyl) amino]-5H,6H,7H,8H- pyrido[3,4-d] pyrimidin-7-yl ⁇ -1H,2H,3H-pyrido[2,3-b] [1,4]oxazine-1- carboxylate To a solution of N-(4-nitrophenyl)-5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine (470.00 mg; 1.69 mmol) and tert-butyl 7-bromo-8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (596.00 mg; 1.69 mmol) in 1,4- dioxane (15.00 mL) were added Cs2CO3 (1162.00 mg; 3.39 mmol) and Pd-PEPPSI-
  • tert-butyl 7- ⁇ 2-[(4-aminophenyl) amino]-5H,6H,7H,8H-pyrido[3,4- d] pyrimidin-7-yl ⁇ -8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4]oxazine-1-carboxylate To a solution of tert-butyl 8-methyl-7- ⁇ 2-[(4-nitrophenyl)amino]-5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-7-yl ⁇ -1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (130.00 mg; 0.20 mmol) in MeOH (5.00 mL) was added Palladium on activated carbon (17.00 mg; 0.02 mmol) in a pressure tank.
  • the resulting mixture was stirred for 1 h at room temperature.
  • the combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 13 synthesis of compound 141,1-dimethyl-N-(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)-2,3- dihydro-1H-isoindol-5-amine [00204] 3,3-dimethyl-2,3-dihydro-1H-isoindol-1-one: To a stirred solution of 2-cyanobenzoic acid (6.00 g; 38.74 mmol) in THF (200.00 mL) was added CH 3 Li (250.00 mL; 400.00 mmol) in portions at -78 o C under N 2 atmosphere.
  • tert-butyl 1,1-dimethyl-5-nitro-2,3-dihydro-1H-isoindole-2- carboxylate To a solution of 1,1-dimethyl-5-nitro-2,3-dihydro-1H-isoindole (1.30 g; 6.76 mmol) in THF (40.00 mL) was added NaH (1.30 g; 32.50 mmol) at 0 o C. The mixture was stirred for 1 h. (Boc) 2 O (4.41 mL; 19.59 mmol) was added and the mixture was allowed to warm to room temperature and stirred for 1 h.
  • tert-butyl 5-amino-1,1-dimethyl-2,3-dihydro-1H-isoindole-2- carboxylate A solution of tert-butyl 1,1-dimethyl-5-nitro-2,3-dihydro-1H-isoindole- 2-carboxylate (2.00 g; 6.84 mmol) and NH4Cl (2.40 g; 43.97 mmol) and Fe (2.40 g; 42.11 mmol) in EtOH (12.00 mL) and water (8.00 mL) was stirred for 2 h at 80 o C under nitrogen atmosphere. The resulting mixture was concentrated under vacuum.
  • tert-butyl 1,1-dimethyl-5-( ⁇ 5H,6H,7H,8H-pyrido[3,4-d] pyrimidin- 2-yl ⁇ amino)-2,3-dihydro-1H-isoindole-2-carboxylate A solution of tert-butyl 5- amino-1,1-dimethyl-2,3-dihydro-1H-isoindole-2-carboxylate (500.00 mg; 1.91 mmol) and 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine hydrochloride (511.00 mg; 2.41 mmol) , Cs2CO3 (1.85 g; 5.39 mmol) , Ephos (200.00 mg; 0.36 mmol), EPhos Pd G4 (200.00 mg; 0.21 mmol) in 1,4-dioxane (10.00 mL) was stirred for 2 h at 100 o
  • Example 14 synthesis of compound 15 N1-[2-(dimethylamino) ethyl]-2-methyl- N4-(6- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro- 2,6naphthyridin-3-yl)benzene-1,4-diamine [00213] N-[2-(dimethylamino) ethyl]-2-methyl-4-nitroaniline: To a stirred mixture of 1-fluoro-2-methyl-4-nitrobenzene (1.00 g; 6.12 mmol) and (2-aminoethyl) dimethylamine (1.14 g; 12.25 mmol) in DMF (10.00 mL) was added K 2 CO 3 (2.67 g; 18.37 mmol) in portions at room temperature.
  • tert-butyl N-[2-(dimethylamino) ethyl]-N-(2-methyl-4-nitrophenyl) carbamate To a stirred solution of N-[2-(dimethylamino)ethyl]-2-methyl-4- nitroaniline (1.26 g; 5.57 mmol) in DCM (13.00 mL) were added 4- Dimethylaminopyridine (DMAP) (0.13 g; 1.11 mmol), TEA (1.78 g; 16.71 mmol) and Boc2O (3.68 g; 16.71 mmol) at 0 o C. The resulting mixture was stirred for 2 d at 30 o C under N 2 atmosphere.
  • DMAP 4- Dimethylaminopyridine
  • tert-butyl N-(4-amino-2-methylphenyl)-N-[2-(dimethylamino) ethyl] carbamate To a stirred solution of tert-butyl N-[2-(dimethylamino)ethyl]-N- (2-methyl-4-nitrophenyl)carbamate (1.00 g; 2.44 mmol) in EtOH (10.00 mL) and water (3.00 mL) were added Fe (0.72 g; 12.21 mmol) and NH 4 Cl (0.82 g; 14.65 mmol) at room temperature. The resulting mixture was stirred for 1 h at 80 o C.
  • tert-butyl N-[2-(dimethylamino) ethyl]-N- ⁇ 2-methyl-4-[(5,6,7,8- tetrahydro-2,6-naphthyridin-3-yl) amino] phenyl ⁇ carbamate To a stirred mixture of tert-butyl N-(4-amino-2-methylphenyl)-N-[2-(dimethylamino)ethyl]carbamate (200.00 mg; 0.65 mmol) and 7-chloro-1,2,3,4-tetrahydro-2,6-naphthyridine (135.00 mg; 0.78 mmol) in 1,4-dioxane (2.00 mL) were added Ephos (37.00 mg; 0.07 mmol), EPhos Pd G 4 (63.00 mg; 0.07 mmol)and Cs 2 CO 3 (668.00 mg; 1.95 mmol) in portions at room temperature.
  • the resulting mixture was stirred for 1 h at 120 o C under N2 atmosphere using a microwave reaction tube.
  • the resulting mixture was extracted with EA.
  • the combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 15 synthesis of compound 162-methyl-N4-(6- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b] [1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)-N1-[2- (morpholin-4-yl)ethyl]benzene-1,4-diamine [00220] 2-methyl-N-[2-(morpholin-4-yl) ethyl]-4-nitroaniline: To a stirred mixture of 2-(morpholin-4-yl)ethan-1-amine (1.86 g; 13.61 mmol) and 1-bromo-2- methyl-4-nitrobenzene (2.00 g; 9.07 mmol) in 1,4-dioxane (30.00 mL) were added Pd 2 (dba) 3 (0.87 g; 0.91 mmol), BINAP (1.19 g; 1.81 m
  • tert-butyl N-(2-methyl-4-nitrophenyl)-N-[2-(morpholin-4-yl) ethyl] carbamate To a stirred solution of 2-methyl-N-[2-(morpholin-4-yl) ethyl]-4- nitroaniline (1.30 g; 4.68 mmol) and di-tert-butyl dicarbonate (3.23 g; 14.05 mmol) in DMF (20.00 mL) were added N,N-dimethylpyridin-4-amine (0.12 g; 0.94 mmol) and TEA (2.06 mL; 14.05 mmol) in portions at room temperature under argon atmosphere.
  • tert-butyl N-(4-amino-2-methylphenyl)-N-[2-(morpholin-4-yl) ethyl] carbamate To a solution of tert-butyl N-(2-methyl-4-nitrophenyl)-N-[2- (morpholin-4-yl) ethyl]carbamate (300.00 mg; 0.74 mmol) in MeOH (10.00 mL) was added Raney-Ni (190.30 mg; 0.22 mmol) at room temperature. The mixture stirring at room temperature for 2 h under H2 atmosphere.
  • tert-butyl N- ⁇ 2-methyl-4-[(5,6,7,8-tetrahydro-2,6-naphthyridin-3- yl) amino] phenyl ⁇ -N-[2-(morpholin-4-yl)ethyl]carbamate To a solution of tert- butyl N-(4-amino-2-methylphenyl)-N-[2-(morpholin-4-yl)ethyl]carbamate (230.00 mg; 0.50 mmol) and 7-chloro-1,2,3,4-tetrahydro-2,6-naphthyridine hydrochloride (157.61 mg; 0.75 mmol) in 1,4-dioxane (15.00 mL) were added Cs2CO3 (512.60 mg; 1.49 mmol), Ephos (56.09 mg; 0.10 mmol) and EPhos Pd G 4 (48.17 mg; 0.05 mmol).
  • Example 16 synthesis of compound 132-(dimethylamino)-N- ⁇ 4-[(7- ⁇ 8-methyl- 1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-2-yl)amino] phenyl ⁇ acetamide [00227] tert-butyl 7-[2-( ⁇ 4-[2-(dimethylamino)acetamido]phenyl ⁇ amino)- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl]-8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazine-1-carboxylate: To a stirred mixture of tert-butyl 7- ⁇ 2-[(4- aminophenyl)amino]
  • Example 17 synthesis of compound 17 N1,2-dimethyl-N4-(7- ⁇ 8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin- 2-yl)-N1-[2-(morpholin-4-yl)ethyl]benzene-1,4-diamine; formic acid [00230] N,2-dimethyl-N-[2-(morpholin-4-yl)ethyl]-4-nitroaniline: To a stirred mixture of 1-fluoro-2-methyl-4-nitrobenzene (384.00 mg; 2.01 mmol) and methyl[2-(morpholin-4-yl)ethyl]amine (319.65 mg; 2.22 mmol) in ACN (6.00 mL) was added K 2 CO 3 (586.28 mg; 4.03 mmol) at room temperature.
  • N1,2-dimethyl-N1-[2-(morpholin-4-yl)ethyl]benzene-1,4-diamine To a solution of N,2-dimethyl-N-[2-(morpholin-4-yl)ethyl]-4-nitroaniline (230.00 mg; 0.81 mmol) in MeOH (4.00 mL) mL was added Raney-Ni (40.00 mg; 0.44 mmol) at room temperature. After stirring for 2 h at room temperature under hydrogen atmosphere, the resulting mixture was filtered. The filter cake was washed with MeOH. The crude product was used in the next step directly without further purification.
  • N1,2-dimethyl-N1-[2-(morpholin-4-yl)ethyl]-N4- ⁇ 5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-yl ⁇ benzene-1,4-diamine To a stirred mixture of tert- butyl 2-[(3-methyl-4- ⁇ methyl[2-(morpholin-4-yl)ethyl]amino ⁇ phenyl)amino]- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (530.00 mg; 0.97 mmol) and TFA (3.00 mL) in DCM (15.00 mL) at room temperature.
  • Example 18 synthesis of compound 186-(1-methanesulfonylcyclopropyl)-N-(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)pyridin-3-amine
  • 2-(bromomethyl)-5-nitropyridine To a stirred solution of 2-methyl- 5-nitropyridine (10.00 g; 70.95 mmol) in CCl4 (100.00 mL) was added NBS (38.66 g; 212.85 mmol) and AIBN (4.76 g; 28.38 mmol) in portions at room temperature.
  • Example 19 synthesis of compound 195-fluoro-6-(methanesulfonylmethyl)-N- (7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)pyridin-3-amine [00246] 5-bromo-2-(bromomethyl)-3-fluoropyridine: To a solution of (5- bromo-3-fluoropyridin-2-yl)methanol (0.99 g; 4.71 mmol) in DCM (30.00 mL) was added PBr3 (0.61 mL; 6.12 mmol) at -20°C.
  • 5-bromo-2-(bromomethyl)-3- fluoropyridine (670.00 mg; 51.5 %)
  • 5-bromo-3-fluoro-2-(methanesulfonylmethyl)pyridine To a stirred solution of 5-bromo-2-(bromomethyl)-3-fluoropyridine (660.00 mg; 2.39 mmol) in DMF (20.00 mL) was added sodium methanesulfinate (1232.00 mg; 11.95 mmol). The resulting mixture was stirred for 4 h at 60 o C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature and was concentrated under reduced pressure.
  • tert-butyl N-[5-fluoro-6-(methanesulfonylmethyl)pyridin-3- yl]carbamate To a stirred mixture of 5-bromo-3-fluoro-2-(methanesulfonylmethyl) pyridine (775.00 mg; 2.53 mmol) and tert-butyl carbamate (469.00 mg; 3.80 mmol) in 1,4-dioxane (20.00 mL) were added Pd2(dba)3 (245.00 mg; 0.25 mmol), Xantphos (297.00 mg; 0.51 mmol) and Cs2CO3 (1738.00 mg; 5.07 mmol) at room temperature.
  • tert-butyl 2- ⁇ [5-fluoro-6-(methanesulfonylmethyl)pyridin-3- yl]amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a solution of 5-fluoro-6-(methanesulfonylmethyl)pyridin-3-amine (300.00 mg; 1.46 mmol) and tert-butyl 7-bromo-8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (513.00 mg; 1.46 mmol) in 1,4-dioxane (20.00 mL) were added Ephos (164.00 mg; 0.29 mmol), Cs2CO3 (999.00 mg; 2.91 mmol) and EPhos Pd G4 (141.00 mg; 0.15 mmol).
  • the mixture was basified to pH [7] with saturated NaHCO3 (aq.).
  • the resulting mixture was extracted with DCM.
  • the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.
  • Example 20 synthesis of compound 206-(2-methanesulfonylpropan-2-yl)-N-(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)pyridin-3-amine
  • tert-butyl 2- ⁇ [6-(2-methanesulfonylpropan-2-yl)pyridin-3- yl]amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred solution of 6-(2-methanesulfonylpropan-2-yl)pyridin-3-amine (210.00 mg; 0.94 mmol) and tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (257.25 mg; 0.94 mmol) in 1,4-dioxane (10.00 mL) was added Pd-PEPPSI-IPentCl 2- methylpyridine (o-picoline) (83.39 mg; 0.09 mmol) and Cs 2 CO 3 (646.81 mg; 1.89 mmol).
  • Example 21 synthesis of compound 216-(methanesulfonylmethyl)-5-methyl-N- (7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)pyridin-3-amine [00264] methyl 3-methyl-5-nitropyridine-2-carboxylate: To a stirred solution of methyl 3-methylpyridine-2-carboxylate (5.00 g; 31.42 mmol) in DCM (10.00 mL) was added TFAA (13.20 g; 59.71 mmol) and nitro-3-oxidanide; tetrabutylazanium (15.10 g; 47.11 mmol) at 0 o C under nitrogen atmosphere.
  • tert-butyl 2- ⁇ [6-(methanesulfonylmethyl)-5-methylpyridin-3- yl]amino ⁇ -5H,6H,7H,8H-pyrido [3,4-d]pyrimidine-7-carboxylate To a solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (278.00 mg; 1.03 mmol) and 6-(methanesulfonylmethyl)-5-methylpyridin-3-amine (220.00 mg; 1.03 mmol) in 1,4-dioxane (20.00 mL) were added Cs2CO3 (707.00 mg; 2.06 mmol), and Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (92.00 mg; 0.10 mmol).
  • the resulting mixture was concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC with the following conditions (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH4HCO3+0.1%NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 18% B to 48% B in 9 min., 48% B; Wave Length: 254 nm; RT1 (min.): 7) to afford 6-(methanesulfonylmethyl)-5-methyl-N-(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)pyridin-3- amine (20.10 mg; 27.7 %) as a yellow solid.
  • Example 22 synthesis of compound 226-methyl-2-[(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl)amino]-4H,5H,6H,7H,8H-pyrazolo[1,5-d][1,4]diazepin-7-on [00274] 2-bromo-4H,5H,6H,7H,8H-pyrazolo[1,5-d][1,4]diazepin-7-one: To a stirred solution of methyl 2-[3-bromo-5-(cyanomethyl)-1H-pyrazol-1-yl]acetate (1.50 g; 5.06 mmol) and Cobalt chloride hexahydrate (2.46 g; 10.11 mmol) in MeOH (50.00 mL) was added Na
  • the resulting mixture was stirred for 1 h at 100 o C under N2 atmosphere.
  • the resulting mixture was diluted with water (15 mL) extracted with EtOAc (3 x 20 mL).
  • the combined organic layers were washed with brine and dried over anhydrous Na2SO4.
  • the resulting mixture was concentrated under reduced pressure.
  • the resulting mixture was stirred for 0.5 h at -78 o C under N2 atmosphere.
  • the resulting mixture was quenched with NaHCO 3 , then diluted with water (15 mL), extracted with DCM (3 x 10 mL).
  • the combined organic layers were washed with brine (15 mL) and dried over anhydrous Na 2 SO 4 .
  • the resulting mixture was concentrated under reduced pressure.
  • Example 23 synthesis of compound 232-methyl-N4-(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)-N1-[2- (morpholin-4-yl)ethyl]benzene-1,4-diamine [00282] 2-methyl-N-[2-(morpholin-4-yl)ethyl]-4-nitroaniline: To a stirred mixture of 2-(morpholin-4-yl)ethan-1-amine (1.86 g; 13.61 mmol) and 1-bromo-2- methyl-4-nitrobenzene (2.00 g; 9.07 mmol) in 1,4-dioxane (30.00 mL) and were added Pd 2 (dba) 3 (0.87 g; 0.91 mmol), BINAP (1.19 g; 1.81
  • tert-butyl N-(4-amino-2-methylphenyl)-N-[2-(morpholin-4- yl)ethyl]carbamate To a solution of tert-butyl N-(2-methyl-4-nitrophenyl)-N-[2- (morpholin-4-yl)ethyl]carbamate (320.00 mg; 0.82 mmol) in MeOH (10.00 mL) was added Raney-Ni (209.76 mg; 0.24 mmol) at room temperature. The mixture was stirred at room temperature for 2 h under H2 atmosphere.
  • tert-butyl N-[2-methyl-4-( ⁇ 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin- 2-yl ⁇ amino)phenyl]-N-[2-(morpholin-4-yl)ethyl]carbamate To a solution of tert- butyl N-(4-amino-2-methylphenyl)-N-[2-(morpholin-4-yl)ethyl]carbamate (150.00 mg; 0.34 mmol) and 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine hydrochloride (112.04 mg; 0.51 mmol) in 1,4-dioxane (10.00 mL) were added Cs2CO3 (351.01 mg; 1.02 mmol), Ephos (38.41 mg; 0.07 mmol) and EPhos Pd G4 (32.99 mg; 0.03 mmol).
  • Example 24 synthesis of compound 24 N-(4-methanesulfonylphenyl)-7- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine
  • tert-butyl 2-[(4-methanesulfonylphenyl)amino]-5H,6H,7H,8H- pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred solution of tert-butyl 2-chloro- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 1.10 mmol) and in 1,4-dioxane (10.00 mL) was added Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (97.25 mg; 0.11 mmol) and Cs 2 CO 3 (754.30 mg; 2.20 mmol).
  • N-(4-methanesulfonylphenyl)-5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine To a stirred solution of tert-butyl 2-[(4- methanesulfonylphenyl)amino]-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (330.00 mg; 0.76 mmol) in DCM (10.00 mL) was added TFA (2.00 mL) in portions at room temperature.
  • Example 25 Synthesis of compound 25 N-[4- (methanesulfonylmethoxy)phenyl]-7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-amine [00294] 1-[(methylsulfanyl) methoxy]-4-nitrobenzene: To a stirred solution of 4-nitrophenol (1.00 g; 6.83 mmol) in DMF (15.00 mL) was added sodium hydride (683.00 mg; 17.08 mmol) at 0°C under nitrogen atmosphere. The resulting mixture was stirred for 10 min.
  • tert-butyl 2- ⁇ [4-(methanesulfonylmethoxy)phenyl]amino ⁇ - 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (350.00 mg; 1.30 mmol) and 4-(methanesulfonylmethoxy)aniline (299.00 mg; 1.30 mmol) in 1,4- dioxane (15.00 mL) were added Cs 2 CO 3 (890.00 mg; 2.59 mmol) and Pd-PEPPSI- IPentCl 2-methylpyridine (o-picoline) (57.00 mg; 0.06 mmol).
  • N-[4-(methanesulfonylmethoxy)phenyl]-5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine To a stirred solution of tert-butyl 2- ⁇ [4- (methanesulfonylmethoxy)phenyl]amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7- carboxylate (290.00 mg; 0.66 mmol) and DCM (5.00 mL) was added TFA (1.00 mL) dropwise at room temperature. The resulting mixture was stirred for 1 h at room temperature.
  • the resulting mixture was stirred for 1 h at room temperature.
  • the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.
  • Example 26 Synthesis of compound 26 N2-[2-(dimethylamino) ethyl]-N5-(6- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b] [1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6- naphthyridin-3-yl)pyridine-2,5-diamine [00302] N-[2-(dimethylamino)ethyl]-5-nitropyridin-2-amine: To a stirred solution of 2-fluoro-5-nitropyridine (1.00 g; 6.69 mmol) and K2CO3 (2.91 g; 20.06 mmol) in DMF (10.00 mL) was added (2-aminoethyl)dimethylamine (0.93 g; 10.03 mmol) dropwise at room temperature.
  • tert-butyl N-[2-(dimethylamino)ethyl]-N-(5-nitropyridin-2- yl)carbamate To a stirred solution of N-[2-(dimethylamino)ethyl]-5-nitropyridin-2- amine (1.28 g; 6.07 mmol) in DCM (3.00 mL) were added DMAP (0.14 g; 1.21 mmol), TEA (1.94 g; 18.20 mmol) and Boc2O (4.01 g; 18.20 mmol) at 0 o C. The resulting mixture was stirred for 1 h at room temperature under N2 atmosphere.
  • tert-butyl N-(5-aminopyridin-2-yl)-N-[2-(dimethylamino) ethyl]carbamate To a stirred solution of tert-butyl N-[2-(dimethylamino)ethyl]-N- (5-nitropyridin-2-yl)carbamate (1.48 g; 4.72 mmol) in EtOH (15.00 mL) and water (5.00 mL) were added Fe (1.39 g; 23.61 mmol) and NH4Cl (1.59 g; 28.33 mmol) at room temperature. The resulting mixture was stirred for 3 h at 80 o C under H 2 atmosphere.
  • tert-butyl N-[2-(dimethylamino)ethyl]-N- ⁇ 5-[(5,6,7,8-tetrahydro- 2,6-naphthyridin-3-yl)amino]pyridin-2-yl ⁇ carbamate To a stirred mixture of tert- butyl N-(5-aminopyridin-2-yl)-N-[2-(dimethylamino)ethyl]carbamate (500.00 mg; 1.72 mmol) and 7-chloro-1,2,3,4-tetrahydro-2,6-naphthyridine (357.00 mg; 2.07 mmol) in 1,4-dioxane (5.00 mL) were added EPhos Pd G 4 (166.00 mg; 0.17 mmol), Ephos (97.00 mg; 0.17 mmol) and Cs2CO3 (1771.00 mg; 5.16 mmol) in portions at room temperature.
  • the resulting mixture was stirred for overnight at 100 o C under N2 atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO4. After filtration, the filtrate was concentrated under reduced pressure.
  • Example 27 Synthesis of compound 272-methyl-4-[(6- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)amino]- N-[2-(morpholin-4-yl)ethyl]benzamide
  • tert-butyl 7- ⁇ [4-(methoxycarbonyl)-3-methylphenyl]amino ⁇ - 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate To a stirred mixture of tert- butyl 7-chloro-1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (400.00 mg; 1.21 mmol) and methyl 4-amino-2-methylbenzoate (400.28 mg; 2.42 mmol) in 1,4-dioxane (12.00 mL) were added Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (107.15 mg; 0.12 mmol) and Cs 2 CO 3 (831.07 mg; 2.42 mmol) at room temperature.
  • Pd-PEPPSI-IPentCl 2-methylpyridine o-picoline
  • Cs 2 CO 3 831.
  • the mixture was stirred for 3 h at 50 o C.
  • the resulting mixture was quenched by ice/water and extracted with EtOAc.
  • the combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 28 Synthesis of compound 28 N2-[2-(dimethylamino)ethyl]-3-methyl- N5-(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-yl)pyridine-2,5-diamine [00316] N-[2-(dimethylamino)ethyl]-3-methyl-5-nitropyridin-2-amine: To a stirred mixture of 2-fluoro-3-methyl-5-nitropyridine (1.00 g; 6.28 mmol) and (2- aminoethyl)dimethylamine (864.64 mg; 9.42 mmol) in DMF (10.00 mL) was added Cs2CO3 (6197.91 mg; 18.83 mmol) in portions at 25 °C under nitrogen atmosphere.
  • tert-butyl N-[2-(dimethylamino)ethyl]-N-(3-methyl-5-nitropyridin- 2-yl)carbamate To a stirred mixture of N-[2-(dimethylamino) ethyl]-3-methyl-5- nitropyridin-2-amine (1.00 g; 4.46 mmol) and (Boc) 2 O (3.14 mL; 13.38 mmol) in DCM (20.00 mL) was added TEA (1424.90 mg; 13.38 mmol) and DMAP (114.69 mg; 0.89 mmol) in portions at 25°C under nitrogen atmosphere.
  • tert-butyl N-(5-amino-3-methylpyridin-2-yl)-N-[2- (dimethylamino)ethyl]carbamate To a stirred mixture of tert-butyl N-[2- (dimethylamino)ethyl]-N-(3-methyl-5-nitropyridin-2-yl)carbamate (1.00 g; 2.96 mmol) and NH 4 Cl (806.94 mg; 14.78 mmol) in EtOH (12.00 mL) and water (8.00 mL) was added Fe (733.93 mg; 11.83 mmol) in portions at 25 °C under nitrogen atmosphere.
  • the resulting mixture was stirred for overnight at 120 °C under N2 atmosphere.
  • the resulting mixture was diluted with water (15 mL), extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (15 mL), dried over anhydrous Na 2 SO 4 .
  • the resulting mixture was concentrated under reduced pressure.
  • N-[4-amino-2-(trifluoromethyl)phenyl]-2-(morpholin-4- yl)acetamide To a stirred mixture of 2-(morpholin-4-yl)-N-[4-nitro-2- (trifluoromethyl)phenyl]acetamide (1.00 g; 3.00 mmol) and NH 4 Cl (844.76 mg; 15.00 mmol) in EtOH (6.00 mL) and water (4.00 mL) was added Fe (707.52 mg; 12.00 mmol) in portions at 25 °C under nitrogen atmosphere. The resulting mixture was stirred for 4 h at 80 °C under nitrogen atmosphere. The resulting mixture was extracted with EA (3 x 50 mL).
  • tert-butyl 2-( ⁇ 4-[2-(morpholin-4-yl) acetamido]-3-(trifluoromethyl) phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred mixture of N-[4-amino-2-(trifluoromethyl)phenyl]-2-(morpholin-4-yl)acetamide (400.00 mg; 1.32 mmol) and tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4- d]pyrimidine-7-carboxylate (540.00 mg; 2.00 mmol) in DMF (10.00 mL) was added Xphos Pd G 3 (120.00 mg; 0.13 mmol), X-PHOS (60.00 mg; 0.12 mmol) and K 2 CO 3 (560.00 mg; 3.85 mmol) in portions at 25
  • the crude product was purified by Prep-HPLC with the following conditions: Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH4HCO3+0.05%NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 29% B to 59% B in 9 min., 59% B; Wave Length: 254 nm; RT1 (min.): 7.
  • tert-butyl 2- ⁇ [2-(2-hydroxy-2-methylpropyl)-2,3-dihydro-1H- isoindol-5-yl]amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred solution of 1-(5-amino-2,3-dihydro-1H-isoindol-2-yl)-2-methylpropan-2-ol (300.00 mg; 1.26 mmol) and tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4- d]pyrimidine-7-carboxylate (428.00 mg; 1.51 mmol) in 1,4-dioxane (15.00 mL) was added Cs 2 CO 3 (862.00 mg; 2.51 mmol) and Pd-PEPPSI-IPentCl 2-methylpyridine (o- picoline) (111.00
  • the resulting mixture was stirred for 16 h at 100 °C under N 2 atmosphere. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.
  • the resulting mixture was stirred for 16 h at 100 °C under N2 atmosphere. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 31 Synthesis of compound 312-(dimethylamino)-N- ⁇ 5-[(6- ⁇ 8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3- yl)amino]pyridin-2-yl ⁇ acetamide
  • 2-(dimethylamino)-N-(5-nitropyridin-2-yl)acetamide To a stirred solution of 5-nitropyridin-2-amine (1.00 g; 6.97 mmol) in DMF (10.00 mL) were added BTFFH (3.48 g; 10.46 mmol), DIEA (4.74 g; 34.86 mmol) and 2- (dimethylamino) acetic acid (2.42 g; 20.92 mmol) at 0°C under N 2 atmosphere.
  • N-(5-aminopyridin-2-yl)-2-(dimethylamino)acetamide To a solution of 2-(dimethylamino)-N-(5-nitropyridin-2-yl)acetamide (780.00 mg; 3.30 mmol) in MeOH (10.00 mL) mL was added Raney-Ni (500.00 mg; 5.54 mmol) at room temperature. The resulting mixture was stirred for 1 h at room temperature under hydrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 20 mL). The filtrate was concentrated under reduced pressure.
  • N-(5-aminopyridin-2-yl)-2-(dimethylamino) acetamide 600.00 mg; 92.6 %) as a red oil.
  • tert-butyl 7-( ⁇ 6-[2-(dimethylamino)acetamido]pyridin-3-yl ⁇ amino)- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate To a stirred solution of N-(5- aminopyridin-2-yl)-2-(dimethylamino) acetamide (258.00 mg; 1.31 mmol) and tert- butyl 7-chloro-1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (300.00 mg; 1.09 mmol) in 1,4-dioxane (5.00 mL) were added EPhos Pd G4 (106.00 mg; 0.11
  • the resulting mixture was stirred for 1 h at 100 °C under N 2 atmosphere. The resulting mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water. The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • the resulting mixture was stirred for 24 h at 120 °C under N 2 atmosphere. The resulting mixture was allowed to cool down to room temperature. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 5 mL). The filtrate was concentrated under reduced pressure.
  • N-(5-aminopyridin-2-yl)-2-(morpholin-4-yl) acetamide To a stirred solution of 2-(morpholin-4-yl)-N-(5-nitropyridin-2-yl) acetamide (2.48 g; 8.38 mmol) in EtOH (15.00 mL) were added Fe (2.47 g; 41.92 mmol) and NH4Cl (2.36 g; 41.92 mmol (dissolved in H2O (10.00 mL)) in portions at room temperature under N2 atmosphere. The resulting mixture was stirred for 1.5 h at 80 °C under N 2 atmosphere.
  • tert-butyl 7-( ⁇ 6-[2-(morpholin-4-yl)acetamido]pyridin-3-yl ⁇ amino)- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate To a stirred solution of N-(5- aminopyridin-2-yl)-2-(morpholin-4-yl) acetamide (280.00 mg; 1.07 mmol) in 1,4- dioxane (5.00 mL) were added tert-butyl 7-chloro-1,2,3,4-tetrahydro-2,6- naphthyridine-2-carboxylate (331.89 mg; 1.17 mmol), EPhos Pd G4 (103.13 mg; 0.11 mmol), Ephos (120.08 mg; 0.21 mmol) and Cesium Carbonate (1097.40 mg; 3.20 mmol) in portions at room temperature under N 2 atmosphere.
  • the resulting mixture was stirred for 1 h at 100 °C under N2 atmosphere.
  • the resulting mixture was diluted with water (15 mL), extracted with EtOAc (3 x 10 mL).
  • the combined organic layers were washed with brine (15 mL) and dried over anhydrous Na 2 SO 4 .
  • the resulting mixture was concentrated under reduced pressure.
  • Example 33 Synthesis of compound 332-(dimethylamino)-N- ⁇ 2-methyl-4-[(6- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6- naphthyridin-3-yl) amino] phenyl ⁇ acetamide
  • tert-butyl 7-[(3-methyl-4-nitrophenyl)amino]-1,2,3,4-tetrahydro- 2,6-naphthyridine-2-carboxylate To a stirred mixture of 3-methyl-4-nitroaniline (499.81 mg; 3.28 mmol; 1.50 eq.) and tert-butyl 7-chloro-1,2,3,4-tetrahydro-2,6- naphthyridine-2-carboxylate (600.00 mg; 2.19 mmol) in 1,4-dioxane (18.00 mL) and were added PEPPSI-IPr (142.44 mg; 0.22 mmol) and Cs2CO3 (1500.83 mg; 4.38 mmol) in portions at 25 o C.
  • N-(3-methyl-4-nitrophenyl)-5,6,7,8-tetrahydro-2,6-naphthyridin-3- amine To a stirred mixture of tert-butyl 7-[(3-methyl-4-nitrophenyl)amino]-1,2,3,4- tetrahydro-2,6-naphthyridine-2-carboxylate (520.00 mg; 1.35 mmol) in DCM (10.00 mL) and was added TFA (2.00 mL) at room temperature. After stirring for 1 h at room temperature, the mixture was concentrated under reduced pressure. The resulting mixture was quenched with water.
  • tert-butyl 7- ⁇ 7-[(4-amino-3-methylphenyl)amino]-1,2,3,4- tetrahydro-2,6-naphthyridin-2-yl ⁇ -8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazine-1-carboxylate To a solution of tert-butyl 8-methyl-7- ⁇ 7-[(3-methyl- 4-nitrophenyl)amino]-1,2,3,4-tetrahydro-2,6-naphthyridin-2-yl ⁇ -1H,2H,3H- pyrido[2,3-b][1,4]oxazine-1-carboxylate (420.00 mg; 0.73 mmol) in MeOH (10.00 mL) was added Raney-Ni (186.79 mg; 0.22 mmol) at room temperature.
  • Example 34 Synthesis of compound 34 N- ⁇ 2-methyl-4-[(6- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl) amino]phenyl ⁇ -2-(morpholin-4-yl)acetamide [00358] tert-butyl 8-methyl-7-[7-( ⁇ 3-methyl-4-[2-(morpholin-4- yl)acetamido] phenyl ⁇ amino)-1,2,3,4-tetrahydro-2,6-naphthyridin-2-yl]- 1H,2H,3H-pyrido[2,3-b] [1,4] oxazine-1-carboxylate: To a stirred mixture of tert- butyl 7- ⁇ 7-[(4-amino-3-methylphenyl
  • Example 35 Synthesis of compound 352-methyl-4-[(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl)amino]-N-(1-methylazetidin-3-yl)benzamide [00361] tert-butyl 2- ⁇ [4-(methoxycarbonyl)-3-methylphenyl]amino ⁇ - 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred mixture of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (1.00 g; 3.02 mmol) and methyl 4-amino-2-methylbenzoate (1.00 g; 6.
  • Example 36 Synthesis of compound 363-methyl-N5-(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)-N2-[2- (morpholin-4-yl)ethyl]pyridine-2,5-diamine [00368] 3-methyl-N-[2-(morpholin-4-yl)ethyl]-5-nitropyridin-2-amine: To a stirred solution of 2-fluoro-3-methyl-5-nitropyridine (2.50 g; 15.21 mmol), Cs2CO3 (10.01 g; 30.43 mmol) in DMF (25.00 mL) was added 2-(morpholin-4-yl)ethan-1- amine (2.50 g; 18.26 mmol) at room temperature.
  • tert-butyl N-(3-methyl-5-nitropyridin-2-yl)-N-[2-(morpholin-4- yl)ethyl]carbamate A solution of 3-methyl-N-[2-(morpholin-4-yl)ethyl]-5- nitropyridin-2-amine (2.10 g; 7.89 mmol), Boc2O (5.00 g; 22.68 mmol), DMAP (100.00 mg; 0.85 mmol) and TEA (3.43 mL; 23.47 mmol) in DCM (10.00 mL) was stirred for overnight at 30 o C under nitrogen atmosphere. The resulting mixture was concentrated under vacuum.
  • tert-butyl N-(5-amino-3-methylpyridin-2-yl)-N-[2-(morpholin-4- yl)ethyl]carbamate A solution of tert-butyl N-(3-methyl-5-nitropyridin-2-yl)-N-[2- (morpholin-4-yl)ethyl]carbamate (1.10 g; 3.00 mmol), NH 4 Cl (810.00 mg; 14.99 mmol) and Fe (810.00 mg; 14.21 mmol) in EtOH (12.00 mL) and water (6.00 mL) was stirred for 2 h at 80 o C under nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with water.
  • tert-butyl N-[3-methyl-5-( ⁇ 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin- 2-yl ⁇ amino)pyridin-2-yl]-N-[2-(morpholin-4-yl)ethyl]carbamate To a stirred solution of tert-butyl N-(5-amino-3-methylpyridin-2-yl)-N-[2-(morpholin-4- yl)ethyl]carbamate (300.00 mg; 0.89 mmol) and 2-chloro-5H,6H,7H,8H-pyrido[3,4- d]pyrimidine hydrochloride (320.00 mg; 1.43 mmol) in 1,4-dioxane (5.00 mL) was added EPhos Pd G 4 (80.00 mg; 0.08 mmol), Ephos (80.00 mg; 0.14 mmol; 0.16) and Cs2CO3 (900.00
  • the crude product was purified by Prep-HPLC with the following conditions: Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH4HCO3+0.1%NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 18% B to 48% B in 8 min., 48% B; Wave Length: 254 nm; RT1 (min.): 7).
  • Example 37 Synthesis of compound 372-[(6- ⁇ 8-chloro-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)amino]-6-methyl- 4H,5H,6H,7H,8H-pyrazolo[1,5-d][1,4]diazepin-7-one [00375] tert-butyl 8-chloro-7-[7-( ⁇ 6-methyl-7-oxo-4H,5H,6H,7H,8H- pyrazolo[1,5-d][1,4]diazepin-2-yl ⁇ amino)-1,2,3,4-tetrahydro-2,6-naphthyridin-2- yl]-1H,2H,3H-pyrido[2,3-b][1,4]ox
  • Example 38 Synthesis of compound 38 N,N-dimethyl-1- ⁇ 2-methyl-4-[(7- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b][1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-2yl) amino] benzoyl ⁇ azetidin-3-amin [00378] tert-butyl 7-[2-( ⁇ 4-[3-(dimethylamino) azetidine-1-carbonyl]-3- methyl phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl]-8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate: To a stirred mixture of 4-[(7- ⁇ 1-[(tert
  • N N-dimethyl-1- ⁇ 2-methyl-4-[(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-2yl) amino] benzoyl ⁇ azetidin-3-amine: To a stirred mixture of tert-butyl 7-[2-( ⁇ 4-[3-(dimethylamino) azetidine-1-carbonyl]-3-methylphenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-7-yl]-8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4]oxazine-1-carboxylate (160.00 mg; 0.23 mmol) and TFA (1.00 mL) in DCM (5.00 m
  • Example 39 Synthesis of 2-methyl-4-[(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido [3,4-d] pyrimidin-2-yl) amino]-N-[2- (morpholin-4-yl) ethyl] benzamide [00381] tert-butyl 8-methyl-7- ⁇ 2-[(3-methyl-4- ⁇ [2-(morpholin-4-yl) ethyl] carbamoyl ⁇ phenyl) amino]-5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-7-yl ⁇ - 1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate: To a stirred mixture of 4-[(7- ⁇ 1-[(tert-butoxy) carbony
  • Example 40 Synthesis of compound 406-[(cyclopropanesulfonyl)methyl]-N-(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d] pyrimidin-2-yl) pyridin-3-amine [00384] 2-(bromomethyl)-5-nitropyridine: To a stirred solution of 2-methyl- 5-nitropyridine (10.00 g; 70.95 mmol) in CCl 4 (100.00 mL) was added NBS (38.66 g; 212.85 mmol) and AIBN (4.76 g; 28.38 mmol) in portions at room temperature.
  • tert-butyl 2-( ⁇ 6-[(cyclopropanesulfonyl) methyl] pyridin-3-yl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d] pyrimidine-7-carboxylate To a stirred solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d] pyrimidine-7-carboxylate (200.00 mg; 0.64 mmol) and 6-[(cyclopropanesulfonyl) methyl] pyridin-3-amine (137.87 mg; 0.64 mmol) in 1,4-dioxane (10.00 mL) was added Pd-PEPPSI-IPentCl 2- methylpyridine (o-picoline) (56.79 mg; 0.06 mmol) and Cs 2 CO 3 (440.46 mg; 1.28 mmol).
  • Example 41 Synthesis of compound 417- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N-(4- ⁇ [(3-methyloxetan-3-yl) methanesulfonyl] methyl ⁇ phenyl)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-amine [00392] (3-methyloxetan-3-yl)methyl 4-methylbenzene-1-sulfonate: To a stirred solution of (3-methyloxetan-3-yl)methanol (5.00 g; 46.51 mmol) in DCM (60.00 mL) was added Et3N (7.84 g; 69.76 mmol) and 4-methylbenzene-1-sulfonyl chloride (10.27 g; 51.16 mmol) in portions at room temperature.
  • tert-butyl 2-[(4- ⁇ [(3-methyloxetan-3- yl)methanesulfonyl]methyl ⁇ phenyl)amino]-5H,6H,7H,8H-pyrido[3,4- d]pyrimidine-7-carboxylate To a stirred solution of tert-butyl 2-chloro- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (220.00 mg; 0.71 mmol) and 4- ⁇ [(3-methyloxetan-3-yl)methanesulfonyl]methyl ⁇ aniline (265.97 mg; 0.71 mmol) in 1,4-dioxane (10.00 mL) was added Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (62.47 mg; 0.07 mmol) and Cs2CO3 (484.
  • Example 42 synthesis of compound 42 (3R)-N,N-dimethyl-1- ⁇ 4-[(7- ⁇ 8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ 5H,6H,7H,8H-pyrido [3,4-d]pyrimidin- 2-yl)amino]benzoyl ⁇ pyrrolidin-3-amine [00403] tert-butyl 2- ⁇ [4(methoxycarbonyl)phenyl]amino ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred mixture of tert-butyl 2-chloro- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (800.00 mg; 2.41 mmol) and methyl 4-aminobenzoate (729.90 mg; 4.83
  • Example 43 synthesis of compound 43 N2,3-dimethyl-N5-(7- ⁇ 8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d] pyrimidin- 2-yl)-N2-[2-(morpholin-4-yl)ethyl]pyridine-2,5-diamine [00409] N,3-dimethyl-N-[2-(morpholin-4-yl)ethyl]-5-nitropyridin-2-amine: To a stirred solution of 2-fluoro-3-methyl-5-nitropyridine (635.00 mg; 3.86 mmol) in DMF (6.00 mL) was added methyl[2-(morpholin-4-yl)ethyl]amine (574.50 mg; 3.86 mmol) and Cs2CO3 (3975.82 mg; 11.59 mmol) in portions at room temperature under N 2 atmosphere
  • N2,3-dimethyl-N2-[2-(morpholin-4-yl)ethyl]pyridine-2,5-diamine To a stirred solution of N,3-dimethyl-N-[2-(morpholin-4-yl)ethyl]-5-nitropyridin-2- amine (1.35 g; 4.62 mmol) in EtOH (9.00 mL) were added Fe (1362.64 mg; 23.12 mmol) and NH 4 Cl (1301.56 mg; 23.12 mmol, dissolved in H 2 O (6.00 mL)) in portions at room temperature under N2 atmosphere. The resulting mixture was stirred for 1 h at 80 o C under N 2 atmosphere.
  • tert-butyl 2-[(5-methyl-6- ⁇ methyl[2-(morpholin-4- yl)ethyl]amino ⁇ pyridin-3-yl)amino]-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7- carboxylate To a stirred solution of N2,3-dimethyl-N2-[2-(morpholin-4- yl)ethyl]pyridine-2,5-diamine (410.00 mg; 1.57 mmol) in 1,4-dioxane (5.00 mL) were added tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (480.92 mg; 1.73 mmol), PEPPSI TM -IPr (138.63 mg; 0.16 mmol) and Cs2CO3 (1078.47 mg; 3.14 mmol) in portions at room temperature
  • the resulting mixture was stirred for 2.5 h at 100°C under N2 atmosphere.
  • the resulting mixture was diluted with water (15 mL), extracted with EtOAc (3 x 10 mL).
  • the combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4.
  • the resulting mixture was concentrated under reduced pressure.
  • the resulting mixture was stirred for 2 h at 100 °C under N2 atmosphere.
  • the resulting mixture was diluted with water (15 mL), extracted with EtOAc (3 x 10 mL).
  • the combined organic layers were washed with brine (15 mL) and dried over anhydrous Na2SO4.
  • the resulting mixture was concentrated under reduced pressure.
  • the resulting mixture was stirred for 1 h at room temperature under N2 atmosphere
  • the resulting mixture was added NaHCO 3 , then diluted with water (15 mL), extracted with DCM (3 x 10 mL).
  • the combined organic layers were washed with brine (15 mL) and dried over anhydrous Na 2 SO 4 .
  • the resulting mixture was concentrated under reduced pressure.
  • Example 44 synthesis of compound 44 N-(2-methoxyethyl)-4-[(7- ⁇ 8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin- 2-yl)amino]benzamide [00416] tert-butyl 7-[2-( ⁇ 4-[(2-methoxyethyl)carbamoyl]phenyl ⁇ amino)- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl]-8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazine-1-carboxylate: To a stirred mixture of 4-[(7- ⁇ 1-[(tert- butoxy)carbonyl]-8-methyl-1H,2H,3H-pyri
  • Example 45 synthesis of compound 452-(dimethylamino)-N- ⁇ 2-methyl-4-[(7- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)amino]phenyl ⁇ acetamide [00419] tert-butyl 7-[2-( ⁇ 4-[2-(dimethylamino)acetamido]-3- methylphenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl]-8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate: To a stirred mixture of tert- butyl 7- ⁇ 2-[(4-amino-3-methylpheny
  • the resulting mixture was stirred for 2 h at 25 o C under nitrogen atmosphere.
  • the reaction was diluted with H 2 O at 25 o C.
  • the resulting mixture was extracted with EA (3 x 50 mL). The combined organic layers were washed with brine and dried over anhydrous MgSO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • the crude product was purified by Prep- HPLC with the following conditions (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH 4 HCO 3 +0.1%NH 4 OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 25% B to 52% B in 8 min., 52% B; Wave Length: 254 nm; RT1 (min.): 7) to afford 2-(dimethylamino)-N- ⁇ 2- methyl-4-[(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl ⁇ acetamide (21.80 mg; 21.3 %) as a yellow solid.
  • Example 46 synthesis of compound 467- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N- ⁇ 3-[(methylamino)methyl]phenyl ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine [00422] tert-butyl N-methyl-N- ⁇ [3-( ⁇ 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin- 2-yl ⁇ amino)phenyl]methyl ⁇ carbamate: To a solution of 2-chloro-5H,6H,7H,8H- pyrido[3,4-d]pyrimidine hydrochloride (400.00 mg; 1.73 mmol) and tert-butyl N-[(3- aminophenyl)methyl]-N-methylcarbamate (431.00 mg; 1.73 mmol) in 1,4-
  • the mixture was basified to pH [7] with saturated NaHCO3 (aq.).
  • the resulting mixture was extracted with DCM.
  • the combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 47 synthesis of compound 476- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N-(2-methyl-2,3-dihydro-1H-isoindol-5-yl)-5,6,7,8-tetrahydro- 2,6-naphthyridin-3-amine [00426] tert-butyl 7-[(2-methyl-2,3-dihydro-1H-isoindol-5-yl)amino]- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate: To a stirred solution of tert- butyl 7-chloro-1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (250.00 mg; 0.91 mmol) and 2-methyl-2,3-dihydro-1H-isoindol-5
  • N-(2-methyl-2,3-dihydro-1H-isoindol-5-yl)-5,6,7,8-tetrahydro-2,6- naphthyridin-3-amine A solution of tert-butyl 7-[(2-methyl-2,3-dihydro-1H- isoindol-5-yl)amino]-1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (310.00 mg; 0.79 mmol) in HCl (g) in MeOH (6.00 mL) was stirred for 1 h at room temperature.
  • Example 48 synthesis of compound 48 N- ⁇ 2-methyl-4-[(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl)amino]phenyl ⁇ -2-(morpholin-4-yl)acetamide [00431] tert-butyl 8-methyl-7-[2-( ⁇ 3-methyl-4-[2-(morpholin-4- yl)acetamido]phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl]- 1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate: To a stirred mixture of tert- butyl 7- ⁇ 2-[(4-amino-3-methylphenyl
  • the resulting mixture was stirred for 2 h at 25 o C under nitrogen atmosphere.
  • the reaction was diluted with H 2 O at 25 o C.
  • the resulting mixture was extracted with EA (3 x 50 mL). The combined organic layers were washed with brine and dried over anhydrous MgSO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • the resulting mixture was stirred for 1 h at -70 o C under nitrogen atmosphere.
  • the reaction was quenched with Na 2 CO 3 (aq.) at -20 o C.
  • the resulting mixture was extracted with EA (3 x 100 mL). The combined organic layers were washed with brine and dried over anhydrous MgSO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC with the following conditions (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH4HCO3+0.05%NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 20% B to 50% B in 8 min., 50% B; Wave Length: 254 nm; RT1 (min.): 7) to afford N- ⁇ 2-methyl-4-[(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl)amino]phenyl ⁇ -2-(morpholin-4-yl)acetamide (21.80 mg; 85.2 %) as a yellow solid.
  • tert-butyl 2-((2-((methylsulfonyl)methyl) pyridin-4-yl) amino)-5,8- dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate To a stirred mixture of 2- (methanesulfonylmethyl)pyridin-4-amine (310.98 mg; 1.67 mmol; 1.50 eq.) and tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 1.11 mmol; 1.00 eq.) in t-BuOH (18.00 mL) and H2O (1.50 mL) were added Pd2(dba)3 (107.21 mg; 0.11 mmol; 0.10 eq.), X-PHOS (111.63 mg; 0.22 mmol; 0.20 eq.) and Cs
  • N-(2-((methylsulfonyl)methyl) pyridin-4-yl)-5,6,7,8- tetrahydropyrido[3,4-d] pyrimidin-2-amine To a stirred mixture of tert-butyl 7- ⁇ [6-(methanesulfonylmethyl) pyridin-3-yl] amino ⁇ -1,2,3,4-tetrahydro-2,6- naphthyridine-2-carboxylate (300.00 mg; 0.68 mmol) in DCM (6.00 mL) and was added TFA (1.00 mL) at room temperature.
  • tert-butyl 8-methyl-7-(2-((2-((methylsulfonyl)methyl)pyridin-4- yl)amino)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-2,3-dihydro-1H- pyrido[2,3-b][1,4]oxazine-1-carboxylate To a solution of 2- (methanesulfonylmethyl)-N- ⁇ 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl ⁇ pyridin-4- amine (110.00 mg; 0.31 mmol) and tert-butyl 7-bromo-8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazine-1-carboxylate (156.75 mg; 0.47 mmol) in 1,4-dio
  • Example 50 Synthesis of compound 507-(8-methyl-2,3-dihydro-1H-pyrido[2,3- b] [1,4] oxazin-7-yl)-N-(3-((methylsulfonyl) methyl) phenyl)-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-2-amine [00442] tert-butyl 2-((3-((methylsulfonyl)methyl) phenyl) amino)-5,8- dihydropyrido[3,4-d] pyrimidine-7(6H)-carboxylate: To a stirred mixture of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 1.11 mmol) and 3-(methanesulfonylmethyl)aniline (231.26 mg; 1.
  • Example 51 Synthesis of compound 516-(8-methyl-2,3-dihydro-1H-pyrido[2,3- b] [1,4] oxazin-7-yl)-N-(6-((methylsulfonyl) methyl) pyridin-3-yl)-5,6,7,8- tetrahydro-2,6-naphthyridin-3-amine
  • 5-bromo-2-((methylsulfonyl) methyl) pyridine To a stirred solution of 5-bromo-2-(bromomethyl) pyridine (100.00 mg; 0.39 mmol) in DMF (1.50 mL) was added sodium methanesulfinate (201.38 mg; 1.95 mmol). The resulting mixture was stirred for 4 h at 65 o C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. After filtration, and filter cake washed with DCM (50 mL), the filtrate was concentrated under reduced pressure to afford 5-bromo-2- (methanesulfonylmethyl) pyridine (90.00 mg; 80.45 %) as a brown solid.
  • tert-butyl (6-((methylsulfonyl) methyl) pyridin-3-yl) carbamate To a stirred mixture of 5-bromo-2-(methanesulfonylmethyl) pyridine (500.00 mg; 1.95 mmol) and tert-butyl carbamate (360.93 mg; 2.93 mmol) in 1,4-dioxane (15.00 mL) was added Pd 2 (dba) 3 (188.09 mg; 0.20 mmol), Xantphos (228.09 mg; 0.39 mmol) and Cs2CO3 (1338.47 mg; 3.90 mmol) at room temperature.
  • tert-butyl 7-((6-((methylsulfonyl)methyl) pyridin-3-yl) amino)-3,4- dihydro-2,6-naphthyridine-2(1H)-carboxylate To a stirred mixture of 6- (methanesulfonylmethyl) pyridin-3-amine (168.24 mg; 0.90 mmol) and tert-butyl 7- chloro-1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (165.00 mg; 0.60 mmol) in 1,4-dioxane (10.00 mL) were added PEPPSI-IPr (39.17 mg; 0.06 mmol; 0.10 eq.) and
  • N-(6-((methylsulfonyl) methyl) pyridin-3-yl)-5,6,7,8-tetrahydro- 2,6-naphthyridin-3-amine To a stirred mixture of tert-butyl 7- ⁇ [6- (methanesulfonylmethyl) pyridin-3-yl] amino ⁇ -1,2,3,4-tetrahydro-2,6-naphthyridine- 2-carboxylate (270.00 mg; 0.56 mmol) in DCM (6.00 mL) and was added TFA (1.00 mL) at room temperature.
  • Example 52 Synthesis of compound 521-methyl-4-(4-((6-(8-methyl-2,3- dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin- 3-yl) amino) phenyl) piperidin-4-ol [00455] 4-(4-((diphenylmethylene)amino) phenyl)-1-methylpiperidin-4-ol: To a stirred solution of 4-(4-bromophenyl)-1-methylpiperidin-4-ol (1.60 g; 5.74 mmol) and diphenylmethanimine (1.32 g; 6.89 mmol) in 1,4-dioxane (20.00 mL) were added Xantphos (42.00 mg; 0.07 mmol), Pd2(dba)3 (73.00 mg; 0.07 mmol
  • tert-butyl 7-((4-(4-hydroxy-1-methylpiperidin-4-yl)phenyl)amino)- 3,4-dihydro-2,6-naphthyridine-2(1H)-carboxylate To a stirred solution of 4-(4- aminophenyl)-1-methylpiperidin-4-ol (282.00 mg; 1.27 mmol)and tert-butyl 7-chloro- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (300.00 mg; 1.06 mmol) in 1,4- dioxane (5.00 mL) were added Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (94.00 mg; 0.11 mmol) and cesium carbonate (1.09 g; 3.18 mmol) in portions at room temperature under N 2 atmosphere.
  • Pd-PEPPSI-IPentCl 2-methylpyridine o-
  • the resulting mixture was stirred for 1 h at 100 o C under N2 atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was poured into water, the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure.
  • the resulting mixture was stirred for overnight at 100 o C under N 2 atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was poured into water, the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine dried over anhydrous Na2SO4 and concentrated under reduced pressure.
  • Example 53 Synthesis of compound 53 Synthesis of compound 7-(8-methyl-2,3- dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)-N-(4-((methylamino)methyl) phenyl)-5,6,7,8-tetrahydropyrido[3,4-d] pyrimidin-2-amine [00462] tert-butyl methyl(4-((5,6,7,8-tetrahydropyrido[3,4-d] pyrimidin-2- yl) amino) benzyl) carbamate: To a solution of 2-chloro-5H,6H,7H,8H-pyrido[3,4- d]pyrimidine hydrochloride (400.00 mg; 1.54 mmol) and tert-butyl N-[(4- aminophenyl)methyl]-N-methylcarbamate (460.00 mg; 1.85 mmol) in D
  • the resulting mixture was stirred for 3 h at room temperature under nitrogen atmosphere.
  • the mixture was basified to pH [7] with saturated NaHCO3 (aq.).
  • the resulting mixture was extracted with DCM.
  • the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.
  • Example 54 Synthesis of compound 546-(8-methyl-2,3-dihydro-1H-pyrido[2,3- b] [1,4] oxazin-7-yl)-N-(2-morpholinopyridin-4-yl)-5,6,7,8-tetrahydro-2,6- naphthyridin-3-amine [00466] tert-butyl 7-((2-morpholinopyridin-4-yl) amino)-3,4-dihydro-2,6- naphthyridine-2(1H)-carboxylate: To a stirred solution of tert-butyl 7-chloro- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (300.00 mg; 1.06 mmol) and 2- (morpholin-4-yl)pyridin-4-amine (220.00 mg; 1.17 mmol) in 1,4-dioxane (3.00 mL) were added
  • N-(2-morpholinopyridin-4-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin- 3-amine To a stirred solution of tert-butyl 7- ⁇ [2-(morpholin-4-yl) pyridin-4-yl] amino ⁇ -1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (380.00 mg; 0.86 mmol) in DCM (3.00 mL) was added TFA (1.00 mL) at room temperature under N 2 atmosphere. The resulting mixture was stirred for 1 h at room temperature under N2 atmosphere. The mixture was allowed to cool down to room temperature.
  • the resulting mixture was stirred for overnight at 100 degrees C under N 2 atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was poured into water, the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine dried over anhydrous Na2SO4 and concentrated under reduced pressure.
  • Example 55 Synthesis of compound 557-(8-methyl-2,3-dihydro-1H-pyrido[2,3- b] [1,4] oxazin-7-yl)-N-(4-(4-methylpiperazin-1-yl)phenyl)-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-2-amine [00471] tert-butyl 2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5,8- dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: To a stirred mixture of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 0.72 mmol) and 4-(4-methylpiperazin-1-yl)aniline (144.42 mg; 0.72
  • Example 56 Synthesis of compound 562-(dimethylamino)-N-(5-((7-(8-methyl- 2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-2-yl)amino)pyridin-2-yl)acetamide
  • 2-chloro-N-(5-nitropyridin-2-yl) acetamide To a stirred solution of 5-nitropyridin-2-amine (2.00 g; 13.66 mmol) and 2-chloroacetyl chloride (2.44 g; 20.49 mmol) in THF (10.00 mL) was added TEA (2.91 g; 27.32 mmol).
  • N-(5-aminopyridin-2-yl)-2-(dimethylamino) acetamide To a solution of 2-(dimethylamino)-N-(5-nitropyridin-2-yl) acetamide (1.38 g; 5.16 mmol) in MeOH (20.00 mL) was added Raney-Ni (0.54 g; 5.93 mmol) at room temperature.
  • tert-butyl 2-((6-(2-(dimethylamino)acetamido)pyridin-3-yl)amino)- 5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate To a stirred solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 0.96 mmol) and N-(5-aminopyridin-2-yl)-2-(dimethylamino)acetamide (187.79 mg; 0.96 mmol) in 1,4-dioxane (15.00 mL) was added Pd-PEPPSI-IPentCl 2- methylpyridine (o-picoline) (85.18 mg; 0.10 mmol) and Cs2CO3 (660.69 mg; 1.93 mmol).
  • Example 57 Synthesis of compound 57 N-[4-(methanesulfonylmethyl) phenyl]- 6- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6- naphthyridin-3-amine: [00484] tert-butyl 7- ⁇ [4-(methanesulfonylmethyl)phenyl]amino ⁇ -1,2,3,4- tetrahydro-2,6-naphthyridine-2-carboxylate: To a solution of tert-butyl 7-chloro- 1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate (400.00 mg; 1.49 mmol) and 4- (methanesulfonylmethyl)aniline (291.00 mg; 1.49 mmol) in 1,4-
  • N-[4-(methanesulfonylmethyl)phenyl]-5,6,7,8-tetrahydro-2,6- naphthyridin-3-amine To a stirred solution of tert-butyl 7- ⁇ [4- (methanesulfonylmethyl)phenyl]amino ⁇ -1,2,3,4-tetrahydro-2,6-naphthyridine-2- carboxylate (550.00 mg; 1.25 mmol) in DCM (10.00 mL) was added TFA (2.00 mL) in portions at room temperature. The mixture was basified to pH [7] with saturated NaHCO 3 (aq.). The resulting mixture was extracted with DCM.
  • the mixture was basified to pH [7] with saturated NaHCO3 (aq.).
  • the resulting mixture was extracted with DCM.
  • the combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • Example 58 Synthesis of compound 586-(methanesulfonylmethyl)-N-(7- ⁇ 8- methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-yl)pyridin-3-amine: [00489] tert-butyl 2-amino-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7- carboxylate: To a stirred solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4- d]pyrimidine-7-carboxylate (2 g; 7.41 mmol) in 1,4-dioxane (10.00 mL) was added NH4OH (10 mL).
  • Example 59 Synthesis of compound 59 N- ⁇ 4-[(dimethylamino)methyl]phenyl ⁇ -7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine; formic acid: [00495] tert-butyl 2-( ⁇ 4-[(dimethylamino)methyl]phenyl ⁇ amino)- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 1.11 mmol) and 4-[(dimethylamino)methyl]aniline (211.05 mg; 1.33 m
  • N- ⁇ 4-[(dimethylamino)methyl]phenyl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine To a stirred solution of tert-butyl 2-( ⁇ 4- [(dimethylamino)methyl]phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7- carboxylate (380.00 mg; 0.99 mmol) in MeOH (2.00 mL) was added HCl (4 N in dioxane) (3.00 mL) at room temperature under N 2 atmosphere. The resulting mixture was stirred for 1 h at room temperature under N2 atmosphere.
  • Example 60 Synthesis of compound 607- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N- ⁇ 3-[(morpholin-4-yl)methyl]phenyl ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine: [00500] 4-[(3-nitrophenyl) methyl] morpholine: To a stirred mixture of 1- (chloromethyl)-3-nitrobenzene (1.00 g; 5.54 mmol) and TEA (2.45 mL; 16.71 mmol) in DCM (15.00 mL) was added morpholine (0.77 mL; 8.40 mmol) in portions at 0 o C.
  • tert-butyl 2-( ⁇ 3-[(morpholin-4-yl)methyl] phenyl ⁇ amino)- 5H,6H,7H,8H-pyrido[3,4-d] pyrimidine-7-carboxylate To a stirred mixture of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 1.08 mmol) and 3-[(morpholin-4-yl)methyl]aniline (330.00 mg; 1.41 mmol) in 1,4- dioxane (5.00 mL) was added Cs2CO3 (910.00 mg; 2.65 mmol) and Pd-PEPPSI- IPentCl 2-methylpyridine (o-picoline) (94.00 mg; 0.11 mmol) in portions at room temperature.
  • N- ⁇ 3-[(morpholin-4-yl)methyl]phenyl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine To a stirred mixture of tert-butyl 2-( ⁇ 3-[(morpholin-4- yl)methyl]phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d] pyrimidine-7-carboxylate (490.00 mg; 1.05 mmol) in MeOH (2.00 mL) was added hydrochloric acid 4.0 M solution in ethyl acetate (5.00 mL; 20.00 mmol) dropwise at 0 o C.
  • the resulting mixture was stirred for 15 min. at room temperature under nitrogen atmosphere.
  • the reaction was added to a solution of 250 mL ice water.
  • the mixture was basified to pH 14 with cold NaOH (aq.).
  • the resulting mixture was extracted with DCM (3 x 50 mL).
  • the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC with the following conditions (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH 4 HCO 3 +0.05 %NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 24% B to 54% B in 9 min., 54% B; Wave Length: 254 nm; RT1 (min.): 7) to afford 7- ⁇ 8-methyl- 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -N- ⁇ 3-[(morpholin-4-yl)methyl]phenyl ⁇ - 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-amine (93.00 mg; 29.7 %) as a white solid.
  • Example 61 Synthesis of compound 617- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N-[3-(4-methylpiperazin-1-yl)phenyl]-5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine: [00507] tert-butyl 2- ⁇ [3-(4-methylpiperazin-1-yl)phenyl]amino ⁇ - 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred mixture of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 0.96 mmol) and 3-(4-methylpiperazin-1-yl)aniline (184.23 mg; 0.96 mmol
  • tert-butyl 8-methyl-7-(2- ⁇ [3-(4-methylpiperazin-1-yl) phenyl] amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl)-1H,2H,3H-pyrido[2,3- b][1,4]oxazine-1-carboxylate To a stirred mixture of N-[3-(4-methylpiperazin-1- yl)phenyl]-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-amine (260.00 mg; 0.69 mmol) and tert-butyl 7-bromo-8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (228.47 mg; 0.69 mmol) in 1,4-dioxane (15.00 mL) were
  • Example 62 Synthesis of compound 623-methyl-N-(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)- 2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine: [00512] 3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine: To a stirred mixture of tert-butyl 7-amino-2,3,4,5-tetrahydro-1H-3-benzazepine-3-carboxylate (500.00 mg; 1.81 mmol) in THF (20.00 mL) was added LiAlH 4 (1M in THF) (4.60 mL; 4.60 mmol) dropwise at 0 o C.
  • tert-butyl 2-[(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7- yl)amino]-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred mixture of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 1.08 mmol) and 3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine (300.00 mg; 1.12 mmol) in 1,4-dioxane (4.00 mL) were added Cs2CO3 (725.00 mg; 2.11 mmol) and Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (94.00 mg; 0.11 mmol) in portions at room temperature.
  • the resulting mixture was stirred for overnight at 90 o C under nitrogen atmosphere. Water was added to the reaction. The resulting mixture was extracted with EA (3 x 30 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure.
  • Example 63 Synthesis of compound 637- ⁇ 8-chloro-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N-[4-(methanesulfonylmethyl)phenyl]-5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine: [00518] tert-butyl 8-chloro-7-(2- ⁇ [4- (methanesulfonylmethyl)phenyl]amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7- yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate: To a stirred solution of tert-butyl 7-bromo-8-chloro-1H,2H,3H-pyrido[2,3-b
  • the resulting mixture was stirred for 6 h at 25 o C under nitrogen atmosphere.
  • the mixture was basified to pH [7] with saturated NaHCO 3 (aq.).
  • the resulting mixture was extracted with DCM.
  • the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the crude product.
  • Example 64 Synthesis of compound 647- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N- ⁇ 4-[(4-methylpiperazin-1-yl)methyl]phenyl ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine: [00521] tert-butyl 2-( ⁇ 4-[(4-methylpiperazin-1-yl)methyl]phenyl ⁇ amino)- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 0.96 mmol) and 4-[(4-methylpiperazin-1-yl) methyl]aniline (
  • N- ⁇ 4-[(4-methylpiperazin-1-yl) methyl]phenyl ⁇ -5H,6H,7H,8H- pyrido[3,4-d] pyrimidin-2-amine To a stirred solution of tert-butyl 2-( ⁇ 4-[(4- methylpiperazin-1-yl)methyl]phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine- 7-carboxylate (330.00 mg; 0.63 mmol) in DCM (15.00 mL) was added TFA (3.00 mL) dropwise at room temperature.
  • Example 65 Synthesis of compound 65 N- ⁇ 3-[(dimethylamino)methyl]phenyl ⁇ -7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine: [00526] Dimethyl [(3-nitrophenyl) methyl] amine: To a stirred mixture of 1- (chloromethyl)-3-nitrobenzene (1.00 g; 5.54 mmol) and TEA (2.45 mL; 16.71 mmol) in DCM (15.00 mL) was added dimethylamine hydrochloride (0.95 g; 11.07 mmol) in portions at 0 o C.
  • tert-butyl 2-( ⁇ 3-[(dimethylamino)methyl]phenyl ⁇ amino)- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred mixture of tert- butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 1.08 mmol) and 3-[(dimethylamino)methyl]aniline (300.00 mg; 1.88 mmol) in 1,4- dioxane (5.00 mL) was added Cs 2 CO 3 (907.00 mg; 2.64 mmol) and Pd-PEPPSI- IPentCl 2-methylpyridine (o-picoline) (94.00 mg; 0.11 mmol) in portions at room temperature.
  • the resulting mixture at was stirred for 30 min. at 0 o C under nitrogen atmosphere.
  • the reaction was diluted with ice water at 0 o C.
  • the mixture was basified to pH 8 with Na 2 CO 3 .
  • the resulting mixture was extracted with EA (3 x 30 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC with the following conditions (Column: XBridge Shield RP18 OBD Column, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH4HCO3+0.05%NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 24% to 52% in 9 min.; Wave Length: 254 nm; RT1 (min.): 7) to afford N- ⁇ 3-[(dimethylamino)methyl]phenyl ⁇ -7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-amine (63.40 mg; 44.4 %) as a yellow solid.
  • Example 66 Synthesis of compound 667- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -N- ⁇ 3-[(4-methylpiperazin-1-yl)methyl]phenyl ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine:
  • tert-butyl 2-( ⁇ 3-[(4-methylpiperazin-1-yl)methyl]phenyl ⁇ amino)- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred mixture of 3- [(4-methylpiperazin-1-yl)methyl]aniline (249.78 mg; 1.16 mmol) and tert-butyl 2- chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300.00 mg; 0.96 mmol) in 1,4-dioxane (12.00 mL) were added Pd-PEPPSI-IPentCl 2-methylpyridine (o- picoline) (85.28 mg; 0.10 mmol) and Cs 2 CO 3 (660.69 mg; 1.93 mmol) in portions at 25 o C.
  • N- ⁇ 3-[(4-methylpiperazin-1-yl)methyl]phenyl ⁇ -5H,6H,7H,8H- pyrido[3,4-d]pyrimidin-2-amine To a stirred mixture of tert-butyl 2-( ⁇ 3-[(4- methylpiperazin-1-yl)methyl]phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine- 7-carboxylate (400.00 mg; 0.91 mmol) in DCM (1.00 mL) and TFA (6.00 mL) at room temperature. After stirring for 1 h at room temperature, the reaction was quenched with H2O (30 mL).
  • tert-butyl 8-methyl-7-[2-( ⁇ 3-[(4-methylpiperazin-1- yl)methyl]phenyl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl]-1H,2H,3H- pyrido[2,3-b][1,4]oxazine-1-carboxylate To a stirred mixture of tert-butyl 7-bromo- 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (140.35 mg; 0.41 mmol) and N- ⁇ 3-[(4-methylpiperazin-1-yl)methyl]phenyl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine (130.00 mg; 0.35 mmol) in 1,4-diox
  • Example 67 Synthesis of compound 672- ⁇ 4-[(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)amino]pyridin-2- yl ⁇ propan-2-ol: [00538] tert-butyl 2- ⁇ [2-(2-hydroxypropan-2-yl)pyridin-4-yl]amino ⁇ - 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a solution of tert-butyl 2-amino-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (180.00 mg; 0.52 mmol) and 2-(4-bromopyridin-2-yl)propan-2-ol
  • Example 68 Synthesis of compound 686-methyl-2-[(6- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)amino]- 4H,5H,6H,7H,8H-pyrazolo[1,5-d][1,4]diazepin-7-one: [00543] tert-butyl 7-( ⁇ 6-methyl-7-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5- d][1,4]diazepin-2-yl ⁇ amino)-1,2,3,4-tetrahydro-2,6-naphthyridine-2-carboxylate: To a stirred solution of 2-amino-6-methyl-4H,5H,6H,7H,8H-pyr
  • the resulting mixture was stirred for overnight at 100 o C under N2 atmosphere.
  • the resulting mixture was diluted with water (50 mL), extracted with EtOAc (3 x 50 mL).
  • the combined organic layers were washed with brine (50 mL) and dried over anhydrous Na 2 SO 4 .
  • the resulting mixture was concentrated under reduced pressure.
  • the resulting mixture was stirred for 1 h at 100 o C under N2 atmosphere.
  • the resulting mixture was diluted with water (50 mL), extracted with EtOAc (3 x 50 mL).
  • the combined organic layers were washed with brine (50 mL) and dried over anhydrous Na2SO4.
  • the resulting mixture was concentrated under reduced pressure.
  • Example 69 Synthesis of compound 69 N-[4-(methanesulfonylmethyl)phenyl]-7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine: [00548]
  • 1-(methanesulfonylmethyl)-4-nitrobenzene To a stirred solution of 1-(bromomethyl)-4-nitrobenzene (500.00 mg; 2.19 mmol) in DMF (15.00 mL) was added sodium methanesulfinate (362.80 mg; 3.52 mmol).
  • tert-butyl 2- ⁇ [4-(methanesulfonylmethyl)phenyl]amino ⁇ - 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (200.0 g; 0.73 mmol) and 4-(methanesulfonylmethyl)aniline (146.70 mg; 0.73 mmol) in 1,4-dioxane (5.00 mL) were added Cs2CO3 (500.00 mg; 1.46 mmol), XPhos Pd G3 (32.00 mg; 0.036 mmol) and Xphos (
  • N-[4-(methanesulfonylmethyl)phenyl]-5H,6H,7H,8H-pyrido[3,4- d]pyrimidin-2-amine To a stirred solution of tert-butyl 2- ⁇ [4- (methanesulfonylmethyl)phenyl]amino ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7- carboxylate (300.00 mg; 0.66 mmol) in DCM (30.00 mL) was added TFA (7.50 mL) in portions at room temperature. The resulting mixture was stirred for 4 h at 25 o C under nitrogen atmosphere.
  • the resulting mixture was stirred for 6 h at 25 o C under nitrogen atmosphere.
  • the mixture was basified to pH [7] with saturated NaHCO 3 (aq.).
  • the resulting mixture was extracted with DCM.
  • the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the crude.
  • Example 70 Synthesis of compound 70 N-(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido [3,4-d] pyrimidin-2-yl)-1-[(1-methyl- 1H-pyrazol-4-yl)methyl]piperidin-4-amine: [00555] tert-butyl N- ⁇ 1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperidin-4- yl ⁇ carbamate: To a stirred mixture of 1-methyl-1H-pyrazole-4-carbaldehyde (1.00 g; 8.63 mmol) and tert-butyl N-(piperidin-4-yl)carbamate (2.00 g; 9.49 mmol) in DCE (20.00 mL) was added STAB (3.85 g; 17.25 mmol) in portions at 25 o C
  • the crude product was purified by Prep-HPLC with the following conditions (Column: Xselect CSH C18 OBD Column 30*150 mm, 5 ⁇ m, ; Mobile Phase A: water (0.1% FA), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 5% B to 25% B in 8 min., 25% B; Wave Length: 254/220 nm; RT1 (min.): 6.8) to afford 1-[(1-methyl-1H-pyrazol-4- yl)methyl]piperidin-4-amine (200.00 mg; 7.1 %) as a yellow oil.
  • tert-butyl 2-( ⁇ 1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperidin-4- yl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred mixture of 1-[(1-methyl-1H-pyrazol-4-yl)methyl] piperidin-4-amine (168.00 mg; 0.80 mmol) and tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (250.00 mg; 0.80 mmol) in 1,4-dioxane (10.00 mL) were added Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (72.00 mg; 0.08 mmol) and Cs 2 CO 3 (551.00 mg; 1.61 mmol) in portions at 25 o C.
  • the crude product was purified by Prep-HPLC with the following conditions (Column: Xselect CSH C18 OBD Column 30*150 mm, 5 ⁇ m, n; Mobile Phase A: water (0.1%FA), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 5% B to 25% B in 8 min., 25% B; Wave Length: 254/220 nm; RT1 (min.): 6.8) to afford 1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperidin-4-amine (20.00 mg; 7.1 %) as a yellow oil.
  • tert-butyl 2-( ⁇ 1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperidin-4- yl ⁇ amino)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred mixture of 1-[(1-methyl-1H-pyrazol-4-yl)methyl] piperidin-4-amine (168.00 mg; 0.80 mmol) and tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (250.00 mg; 0.80 mmol) in 1,4-dioxane (10.00 mL) were added Pd-PEPPSI-IPentCl 2-methylpyridine (o-picoline) (72.00 mg; 0.08 mmol) and Cs2CO3 (551.00 mg; 1.61 mmol) in portions at 25 o C.
  • Example 71 Synthesis of compound 71 methyl N- ⁇ 4-[(7- ⁇ 8-methyl-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl)amino]phenyl ⁇ carbamate: [00562] 2-( ⁇ 4-[(methoxycarbonyl)amino]phenyl ⁇ amino)-5H,6H,7H,8H- pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of tert-butyl 2-chloro- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (400.00 mg; 1.46 mmol) and methyl N-(4-aminophenyl)carbamate (291.00 mg; 1.75 mmol)
  • the resulting mixture was stirred for 1 h at 25 o C under N2 atmosphere.
  • the resulting mixture was basified to pH 9 with Na2CO3 (aq.), extracted with EtOAc (4 x 100 mL).
  • the combined organic layers were concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC with the following conditions ( Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5 ⁇ m; Mobile Phase A: water (10 mmol/L NH 4 HCO 3 +0.05 %NH 4 OH), Mobile Phase B: ACN; Flow rate: 60 mL/min.; Gradient: 20% B to 50% B in 8 min., 50% B; Wave Length: 254 nm; RT1 (min.): 7) to afford methyl N- ⁇ 4-[(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3- b][1,4]oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2- yl)amino]phenyl ⁇ carbamate (14.00 mg; 8.3%) as a white solid.
  • Example 72 Synthesis of compound 72 N-(7- ⁇ 8-methyl-1H,2H,3H-pyrido[2,3-b] [1,4] oxazin-7-yl ⁇ -5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl)-2-(4- methylpiperazin-1-yl)pyridin-4-amine: B l [00567] 1-methyl-4-(4-nitropyridin-2-yl)piperazine: To a stirred solution of 2-chloro-4-nitropyridine (5.00 g; 29.96 mmol) and 1-methylpiperazine (3.95 g; 37.45 mmol) in DMF (50.00 mL) and water (50.00 mL) was added DIEA (8151.78 mg; 59.92 mmol).
  • tert-butyl 2- ⁇ [2-(4-methylpiperazin-1-yl)pyridin-4-yl]amino ⁇ - 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate To a solution of tert-butyl 2-chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (400.00 mg; 1.48 mmol) and 2-(4-methylpiperazin-1-yl) pyridin-4-amine (340.00 mg; 1.48 mmol) in 1,4-dioxane (15.00 mL) were added Cs2CO3 (1017.00 mg; 2.97 mmol), and Pd- PEPPSI-IPentCl 2-methylpyridine (o-picoline) (131.00 mg; 0.15 mmol).
  • Example 73 Synthesis of compound 73 N-(5-((7-(8-methyl-2,3-dihydro-1H- pyrido[2,3-b][1,4]oxazin-7-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl)amino)pyridin-2-yl)acetamide
  • tert-butyl 2-[(6-acetamidopyridin-3-yl)amino]-5H,6H,7H,8H- pyrido[3,4-d]pyrimidine-7-carboxylate To a stirred solution of tert-butyl 2-chloro- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (450 mg; 1.64 mmol)and N-(5- aminopyridin-2-yl)acetamide (287 mg; 1.80
  • N-[5-( ⁇ 5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-2-yl ⁇ amino)pyridin- 2-yl]acetamide To a stirred mixture of tert-butyl 2-[(6-acetamidopyridin-3- yl)amino]-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (380 mg; 0.97 mmol) in DCM (20 mL) was added TFA (4 mL) dropwise at 25 degrees C. The resulting mixture was stirred for 2 h at 25degrees C under nitrogen atmosphere. The resulting mixture was concentrated under vacuum.
  • Example 74 Synthesis of compound 742-fluoro-N-methyl-4-((7-(8-methyl-2,3-dihydro- 1H-pyrido[2,3-b][1,4]oxazin-7-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl)amino)benzamide
  • 2-fluoro-N-methyl-4-nitrobenzamide To a stirred solution of 2- fluoro-4-nitrobenzoic acid (2 g; 10.48 mmol) in DMF (10 mL) was added SOCL2 (0.91 mL; 11.98 mmol) dropwise at -5 degree C under N 2 atmosphere.
  • the resulting mixture was stirred for 1 h at room temperature under N 2 atmosphere.
  • the combined organic layers were washed with brine (50 mL) and dried over anhydrous Na2SO4.
  • the resulting mixture was concentrated under reduced pressure.
  • Example 75 Synthesis of compound 757-(8-methyl-2,3-dihydro-1H-pyrido[2,3- b][1,4]oxazin-7-yl)-N-(2-(methylsulfonyl)pyridin-4-yl)-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-2-amine
  • tert-butyl 2-[(2-methanesulfonylpyridin-4-yl)amino]- 5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate A solution of tert-butyl 2- chloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate (300 mg; 1.11 mmol), 2- methanesulfonylpyridin-4-amine (201.61 mg; 1.11 mmol), Xphos Pd G3 (99.10 mg; 0.11 mmol), Xphos (55.81 mg; 0.11 mmol) and K2CO3 (323.62 mg; 2.22 mmol) in 1,4-dioxane (20 mL) was stirred for 2 h at 100 degrees C under N 2 atmosphere.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2023/066601 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors Ceased WO2023220541A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202380052662.0A CN119546610A (zh) 2022-05-10 2023-05-04 作为HPK1抑制剂的四氢吡啶并[3,4-d]嘧啶
AU2023267747A AU2023267747A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
EP23728556.4A EP4522618A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
CA3250387A CA3250387A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-D]pyrimidine compounds used as HPK1 inhibitors
IL316818A IL316818A (en) 2022-05-10 2023-05-04 Tetrahydropyrido[4,3-D]pyrimidine compounds as HPK1 inhibitors
JP2024566233A JP2025521083A (ja) 2022-05-10 2023-05-04 ＨＰＫ１阻害剤としてのテトラヒドロピリド［３，４－ｄ］ピリミジン化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263340191P 2022-05-10 2022-05-10
US63/340,191 2022-05-10
US202263383190P 2022-11-10 2022-11-10
US63/383,190 2022-11-10

Publications (1)

Publication Number Publication Date
WO2023220541A1 true WO2023220541A1 (en) 2023-11-16

Family

ID=86688794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/066601 Ceased WO2023220541A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors

Country Status (9)

Country Link
US (1) US20240025922A1 (enExample)
EP (1) EP4522618A1 (enExample)
JP (1) JP2025521083A (enExample)
CN (1) CN119546610A (enExample)
AU (1) AU2023267747A1 (enExample)
CA (1) CA3250387A1 (enExample)
IL (1) IL316818A (enExample)
TW (1) TW202400612A (enExample)
WO (1) WO2023220541A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210407A1 (en) * 2024-04-01 2025-10-09 Merck Patent Gmbh (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183964A1 (en) * 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183964A1 (en) * 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HERNANDEZ S. ET AL., CELL REPORTS, vol. 25, 2018, pages 80 - 94
J. ORG. CHEM., vol. 62, no. 21, 1997
JR-WEN SHUI, NATURE IMMUNOLOGY, vol. 8, 2007, pages 84 - 91
LINNEY IAN D ET AL: "Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 31, no. 10, 20 May 2021 (2021-05-20), GB, pages 893 - 910, XP093004903, ISSN: 1354-3776, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.1080/13543776.2021.1924671?needAccess=true> DOI: 10.1080/13543776.2021.1924671 *
LIU ET AL., PLOS ONE, 26 March 2019 (2019-03-26)
PHILIP J. KOCIENSKI: "Protecting Groups", 1994, GEORG THIEME VERLAG
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
THEODORA W. GREENEPETER G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY INTERSCIENCE
YOU D., J. IMMUNOTHER. CANCER, 2021

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210407A1 (en) * 2024-04-01 2025-10-09 Merck Patent Gmbh (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer

Also Published As

Publication number Publication date
TW202400612A (zh) 2024-01-01
CA3250387A1 (en) 2023-11-16
AU2023267747A1 (en) 2024-11-07
JP2025521083A (ja) 2025-07-08
IL316818A (en) 2025-01-01
CN119546610A (zh) 2025-02-28
US20240025922A1 (en) 2024-01-25
EP4522618A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12233062B2 (en) Heterocyclic derivatives useful as SHP2 inhibitors
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
AU2019216728B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
RU2617405C2 (ru) Пиридоновые и азапиридоновые соединения и способы применения
CN111867590B (zh) Atr激酶的杂环抑制剂
EP4010335A1 (en) Shp2 inhibitors
CA3189912A1 (en) Bicyclic compounds, compositions and use thereof
AU2025226693A1 (en) Monoacylglycerol lipase modulators
MD3483164T2 (ro) Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
WO2018183964A1 (en) Isoquinolines as inhibitors of hpk1
EP2945939A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
CA2922230A1 (en) Biaryl acetamide compounds and methods of use thereof
CA2821712A1 (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors
US20240109900A1 (en) Azabicyclic shp2 inhibitors
JP2023534837A (ja) アンドロゲン受容体モジュレーターとしてのインドール化合物
EP4313983A1 (en) (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4&#39;h,6&#39;h-spiro[piperidine-4,5&#39;-pyrrolo [1,2-b]pyrazol]-4&#39;-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
EP4522618A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
TW202440086A (zh) 作為激酶抑制劑之雙環脲
TW202610638A (zh) 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法
BR112014010459B1 (pt) Compostos e composição farmacêutica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23728556

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023267747

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 316818

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2023267747

Country of ref document: AU

Date of ref document: 20230504

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024566233

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2023728556

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023728556

Country of ref document: EP

Effective date: 20241210

WWE Wipo information: entry into national phase

Ref document number: 202380052662.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202380052662.0

Country of ref document: CN